Medizinische Behandlungsmaßnahmen

  • H. Pichlmaier
  • G. Spilker
  • G. Germann
  • M. H. Hackenbroch
  • J. Rütt
  • S. Said
  • W. Kruis
  • R.-P. Müller
  • R. Zankovich
  • M. Pfreundschuh
  • V. Diehl
  • I. Krüger
  • G. Friedmann
  • W. Gross-Fengels
  • H. O. Klein
  • W. F. Jungi
  • I. Jonen-Thielemann
  • J. M. Müller
  • D. Zech
  • W. Buzello

Zusammenfassung

Ein maligner Primärtumor ist inkurabel, wenn er nicht entfernt oder seine Entfernung wegen der damit verbundenen Folgen nicht hingenommen werden kann und wenn es keine kurativ wirksame konservative Behandlung gibt. Die nichtchirurgische kurative Behandlung ist bis heute als alleinige Maßnahme nur bei wenigen Organtumoren möglich, so daß sich das Schicksal des Kranken meistens mit der Frage nach der chirurgischen Kurabilität entscheidet. Es lag nahe zu versuchen, durch möglichst weitgehende Radikalität des Eingriffs die Grenzen auszudehnen. Dieses Konzept hat für viele Tumoren enttäuscht und ist zum Teil wieder verlassen (z. B. Pankreaskarzinom, Rektumkarzinom, nach unserer Meinung Ösophaguskarzinom, gynäkologische Karzinome u. a.). Für verschiedene Geschwülste wurden kombinierte Schemata der primären Behandlung (Operation, Bestrahlung, Chemotherapie, Immuntherapie) entwickelt und dabei eine weniger radikale und weniger verstümmelnde Operation als Teil eingefügt (z. B. Analkarzinom, Extremitätensarkome, verschiedene kindliche Malignome wie Neuroblastome oder Wilms-Tumore, differenzierte Schilddrüsenkarzinome u.a.).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Adson MA (1987) Resection ofliver metastases - when is it worthwhile? World J Surg 11: 511PubMedGoogle Scholar
  2. 2.
    Bross IDJ, Blumenson E (1976) Metastatic sites that produce generalized cancer: Identification and kinetics of generalized sites. In: Weiss L (ed) Fundamental aspects of metastasis. North-Holland, Amsterdam New YorkGoogle Scholar
  3. 3.
    Eder M (1987) In: Schildberg FW (Hrsg) Chirurgische Behandlung von Tumormetastasen. Melsungen, Medizinische Mitteilungen 58: 49Google Scholar
  4. 4.
    Eigler FW, Gross E, Heckemann R (1985) Wertigkeit der diagnostischen Verfahren und Nachsorgeprobleme bei lokalen und regionalen Tumorrezidiven im Gastrointestinaltrakt. Chirurg 56: 485PubMedGoogle Scholar
  5. 5.
    Herfarth Ch, Schlag P, Hohenberger P (1985) Therapeutische Möglichkeiten bei locoregionären Rezidiven der Carcinome des Gastrointestinaltraktes. Chirurg 56: 492PubMedGoogle Scholar
  6. 6.
    Junginger Th, Wahl W, Pichlmaier H (1989) Die chirurgische Behandlung des Magenfrühkarzinoms. Langenbecks Arch Chir 374: 175–180PubMedGoogle Scholar
  7. 7.
    Keller R (1985) Surgical intervention and metastases. In: Metzger U, Largiadèr F, Senn HJ (eds) Perioperative chemotherapy. Springer, Berlin Heidelberg New York Tokyo (Recent results in cancer research, vol 98)Google Scholar
  8. 8.
    Kern KA, Pass HI, Roth JA (1987) Surgical treatment of pulmonary metastases. In: Rosenberg SA (ed) Surgical treatment of metastatic cancer. Lippincott, PhiladelphiaGoogle Scholar
  9. 9.
    Kinnaert P, Mahieu A, van Geertruyden M (1983) Effect of surgical trauma on delayed type hypersensitivity. J Surg Res 34: 227PubMedGoogle Scholar
  10. 10.
    Liotta LA (1987) Overview of the biology of cancer invasion and metastases. In: Rosenberg SA (ed) Surgical treatment of metastatic cancer. Lippincott, PhiladelphiaGoogle Scholar
  11. 11.
    Löhrs U (1986) Heterogenität von Metastasen. In: Schildberg FW (Hrsg) Chirurgische Behandlung von Tumormetastasen. Melsungen, Medizinische Mitteilungen 58Google Scholar
  12. 12.
    Metzger U, Röthlin M, Largiadèr F (1988) Perioperative Chemotherapy bei gastrointestinalem Carcinom. Chirurg 59: 225PubMedGoogle Scholar
  13. 13.
    Mountain CF (1977) A surgeon’s insight into tumor behavior. In: Williams TE, Wilson HE, Yohn DS (eds) Perspective lung cancer. Karger, BaselGoogle Scholar
  14. 14.
    Parrott NR, Lennard TWJ, Taylor RMR, Sehlton BK, Jonston IDA (1986) Effect of peri operative blood transfusion on recurrence of colorectal cancer. Br J Surg 73: 970PubMedGoogle Scholar
  15. 15.
    Pichlmaier H, Grundmann R (1989) Transplantation and cancer. In: Veronesi U (ed) European Handbook of Surgical Oncology. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  16. 16.
    Pichlmaier H (1988) Das kolorektale Karzinom. Arzt und Krankenhaus 5: 165–173Google Scholar
  17. 17.
    Raab M, Stützer H, Walgenbach S, Junginger Th (1985) Einfluß der chirurgischen Behandlungs-methode auf die Prognose des Magenfrühkarzinoms. Helv Chir Acta 52: 237–240PubMedGoogle Scholar
  18. 18.
    Schildberg FW, Meyer G (1988) Palliative Operationsverfahren beim fortgeschrittenen Coloncarcinom. Chirurg 59: 625PubMedGoogle Scholar
  19. 19.
    Shields TW (1977) Thoughts, concerning the management of patients with carcinoma of the lung. In: Williams TE, Wilson HE, Yohn DS (eds) Perspectives in lung cancer. Karger, BaselGoogle Scholar
  20. 20.
    Slade MS, Simmons RL, Eunice E, Greenberg LJ (1975) Immunodepression after major surgery in normal patients. Surgery 78: 363PubMedGoogle Scholar
  21. 21.
    Tarpley JL, Twomey PL, Kattalona WJ, Chretian PD (1977) Suppression of cellular immunity by anesthesia and operation. J Surg Res 22: 195PubMedGoogle Scholar
  22. 22.
    Vogt-Moykopf I, Branscheid D, Bülzebruck H, Probst G (1989) Aktuelle Aspekte der neuen Stadieneinteilung beim Bronchialcarcinom und ihre klinischen Konsequenzen. Chirurg 60: 16PubMedGoogle Scholar
  23. 23.
    Weese JL, Ottery FD, Emoto SE (1986) Do operations facilitate tumor growth? An experimental model in rats. Surgery 100: 273PubMedGoogle Scholar
  24. 24.
    Weiden PL, Beam MA, Shultz P (1987) Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence. Cancer 60: 870PubMedGoogle Scholar
  25. 25.
    Willig GW, Hajdu SI (1973) Histological benign teratoid metastasis of testicular embryonal carcinoma: report of five cases. Am J Chir Pathol 59: 338Google Scholar
  26. 26.
    Wilkens EW, Scanell JG, Graver JG (1978) Four decades of experience with resections for bronchogenic carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 76: 364Google Scholar
  27. 1.
    Ariyan S (1980) Pectoralis major, sternomastoid and other musculocutaneous flaps for head and neck reconstruction. Clin Plast Surg 7: 89PubMedGoogle Scholar
  28. 2.
    Bakamjian VY, Long M, Rigg B (1971) Experience with the medially based deltopectoral flap in reconstructive surgery of the head and neck. Br J Plast Surg 24: 17406Google Scholar
  29. 3.
    Bekamjian VY, Cervino L, Miller S, Hentz VR (1973) The concept of cure and palliation by surgery in advanced cancer of the head and neck. Am J Surg 126: 482Google Scholar
  30. 4.
    Bertotti JA (1979) Trapezius musculocutaneous island flap in the repair of major head and neck cancer. Plast Reconstr Surg 65: 1Google Scholar
  31. 5.
    Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902PubMedGoogle Scholar
  32. 6.
    Brones M F, Wheeler ES, Lesavoy MA (1982) Restoration of elbow flexion and arm contour with the latissimus dorsi myocutaneous flap. Plast Reconstr Surg 69: 329PubMedGoogle Scholar
  33. 7.
    Caroll RE, Kleinmann WB (1979) Pectoralis major transplantation to restore elbow flexion to the paralytic limb. J Hand Surg (Br) 4: 501Google Scholar
  34. 8.
    Chicarilli ZN, Ariyan S, Cuono CB (1986) Single stage repair of complex scalp and cranial defects with free radial forearm flap. Plast Reconstr Surg 77: 577PubMedGoogle Scholar
  35. 9.
    Conley J (1972) Use of composite flaps containing bone for major repairs in the head and neck. Plast Reconstr Surg 49: 22Google Scholar
  36. 10.
    Cuono CB, Ariyan S (1985) Versalility and safety of flap coverage for wide exzision of cutaneous melanoma. Plast Reconstr Surg 76: 28Google Scholar
  37. 11.
    Daniel RK (1973) Direct transfer of skin flaps by microvascular anastomoses. Masters thesis, McGill University MontrealGoogle Scholar
  38. 12.
    Daniel RK (1978) Mandibular reconstruction with free tissue transfers. Ann Plast Surg 1: 346PubMedGoogle Scholar
  39. 13.
    Daniel RK, Kerrigan CL (1979) Skin flaps: An anatomical and hemodynamic approach. Clin Plast Surg 6: 181PubMedGoogle Scholar
  40. 14.
    Dufresne C, Cutting C, Valauri F, Klein M, Colen S, McGarthy JG (1987) Reconstruction of mandibular and floor of mouth defects using the trapezius osteomyocutaneous flap. Plast Reconstr Surg 79: 687PubMedGoogle Scholar
  41. 15.
    Donski PK, Buechler U, Tschopp HM (1982) Surgical dissection of the fibula for free microvascular transfer. Chir Plast 6: 15Google Scholar
  42. 16.
    Elder DE, Heiberger RM, LaRossa D et al. (1983) Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg 71: 66PubMedGoogle Scholar
  43. 17.
    Hentz VR, Pearl RM (1983) The irreplaceable free flap: Skeletal reconstruction by microvascular free bone transfer. Ann Plast Surg 10: 36PubMedGoogle Scholar
  44. 18.
    Hester TR, McConnel FM, Nahai F, Jurkiewicz MJ, Brown RG (1980) Reconstruction of esophagus, hypopharynx, and oral cavity using free jejunal transfer. Am J Surg 140: 487PubMedGoogle Scholar
  45. 19.
    Hodges P, Tebbetts JB (1984) Principles of flaps. Selected readings. Plast Reconstr Surg 3: 1Google Scholar
  46. 20.
    Lang NP, Stair JM, Degges RD, Thompson C, Garner M, Baker GF, Westbrook KC (1984) Melanoma today does not require radical Surgery. Am J Surg 149: 723Google Scholar
  47. 21.
    Larson DL (1985) What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 5: 397Google Scholar
  48. 22.
    Latham WD (1966) Operative treatment for post radiation defects of the chest wall. Am Surg 32: 700PubMedGoogle Scholar
  49. 23.
    Logan SE, Mathes SJ (1984) The use of a rectus abdominis myocutaneous flap to reconstruct a groin defect. Br J Plast Surg 37: 351PubMedGoogle Scholar
  50. 24.
    Longmire WP jr (1947) A modification of the Roux technique for antethoracic esophageal reconstruction - Anastomosis of the mesenteric and internal mammary blood vessels. Surgery 22: 94PubMedGoogle Scholar
  51. 25.
    McCarthy JG, Haagensen CD, Herter FP (1974) The role of groin dissection in the management of melanoma of the lower extremity. Ann Surg 179: 156PubMedGoogle Scholar
  52. 26.
    McGovern VJ, Shaw HM, Milton GW, Farago GA (1979) Prognostic significance of the histological features of malignant melanoma. Histopathology 3: 385PubMedGoogle Scholar
  53. 27.
    McGregor JC, Palmer JH (1985) A critical review of flap repairs in the lower limb - One unit’s experience over the past five years. Chir Plastica 8: 95Google Scholar
  54. 28.
    Nozaki M, Huang TT, Hayashi M, Endo M, Hirayama T (1985) Reconstruction of the pharyngoesophageous following pharyngoesophagectomy and irradiation therapy. Plast Reconstr Surg 76: 386PubMedGoogle Scholar
  55. 29.
    Olivari N (1976) The latissimus flap. Br J Plast Surg 29: 126PubMedGoogle Scholar
  56. 30.
    Ostrup LT, Fredrickson JM (1975) Reconstruction of mandibular defects after irradiation using free living bone grafts by microvascular anastomoses. Plast Reconstr Surg 55: 563PubMedGoogle Scholar
  57. 31.
    Ponten B (1981) The fasciocutaneous flap: its use in soft tissue defects of the lowerleg. Br J Plast Surg 34: 215PubMedGoogle Scholar
  58. 32.
    Pitt TTE (1980) Aspects of surgical treatment for malignant melanoma. Clin Exp Dermatol 5: 313Google Scholar
  59. 33.
    Radovan C (1984) Tissue expansion in soft-tissue reconstruction. Plast Reconstr Surg 74: 482PubMedGoogle Scholar
  60. 34.
    Rees RS, Ivey GL, Shack BR, Franklin JD, Lynch JB (1986) Pectoralis major musculocutaneous flaps: Long-term follow-up of hypopharyngeal reconstruction. Plast Reconstr Surg 77: 586PubMedGoogle Scholar
  61. 35.
    Roberts RE, Douglass FM (1961) Replacement of the cervical esophagus and hypopharynx by a revascularized free jejunal autograft. N Engl J Med 264: 342PubMedGoogle Scholar
  62. 36.
    Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW (1983) Local and intransit metastasis following definitive excision for primary cutaneous malignant melanoma. Ann Surg 98: 65Google Scholar
  63. 37.
    Rovira-Vila R, Ferreira BJ, Guinot A (1985) Transfer of vascularized extensor tendons from the foot to the hand with a dorsalis pedis flap. Plast Reconstr Surg 76: 421Google Scholar
  64. 38.
    Soutar DS, Scheker LR, Tanner NSB, McGregor IA (1983) The radial forearm flap: a versatile method for intraoral reconstruction. Br J Plast Surg 36: 1PubMedGoogle Scholar
  65. 39.
    Swartz WM, Banis JC, Newton DN, Ramasastry SS, Jones NF, Acland R (1986) The osteocutaneous scapular flap for mandibular and maxillary reconstruction. Plast Reconstr Surg 77: 530PubMedGoogle Scholar
  66. 40.
    Tansini I (1906) Sopra iI mio nuovo processo di amputazione della mammaella. Gazz Med Ital 57: 141Google Scholar
  67. 41.
    Taylor GI, Daniel RK (1973) The free flap: Composite tissue transfer by vascular anastomosis. Aust NZ J Surg 31: 17Google Scholar
  68. 42.
    Taylor GI., Corlett RJ, Boyd JB (1984) The versatile deep inferiorepigastric (inferior rectus abdominis) flap. Br J Plastic Surg 37: 330Google Scholar
  69. 43.
    Tizian C, Borst HG, Berger A (1985) Treatment of total sternal necrosis using the latissimus dorsi muscle flap. Plast Reconstr Surg 76: 703PubMedGoogle Scholar
  70. 44.
    Treidman L, McNeer G (1963) Prognosis with local metastasis and recurrence in malignant melanoma. Ann NY Acad Sci 100: 123PubMedGoogle Scholar
  71. 45.
    Wei FG, Chen HC, Chuang CC, Noordhoff SM (1986) Fibular osteoseptocutaneous flap: Anatomic study and clinical application. Plast Reconstr Surg 78: 191PubMedGoogle Scholar
  72. 46.
    Zuker RM, Manktelow RT (1986) The dorsalis pedis free flap: Technique of elevation, foot closure, and flap application. Plast Reconstr Surg 77: 93PubMedGoogle Scholar
  73. 1.
    Baumgartner-Ritter R (1981) Orthesen. In: Witt AN, Rettig H, Schlegel KF, Hackenbroch M, Hupfauer W (Hrsg) Orthopädie in Praxis und Klinik, Bd II. Thieme, StuttgartGoogle Scholar
  74. 2.
    Hohmann D, Uhlig R (1982) Orthopädische Technik. Enke, StuttgartGoogle Scholar
  75. 3.
    Jäger M, Wirth CJ (1986) Praxis der Orthopädie. Thieme, StuttgartGoogle Scholar
  76. 1.
    Arlt B, Graßhoff H, Strelow M (1986) Die palliative Infrarot-Kontakt-Coagulation beim tiefsitzenden Rektumcarcinom. Chirurg 57: 469PubMedGoogle Scholar
  77. 2.
    Bueß G, Theiß R, Günter M, Hutterer F, Hepp M, Pichlmaier H (1984) Endoskopische Operationen zur Polypabtragung im Rektum. Coloproctology 5: 254Google Scholar
  78. 3.
    Campbell WB (1987) Transanal resection in the palliation of rectal cancer. Ann Acad Med 16: 466Google Scholar
  79. 4.
    Eisenstat TE, Deak ST, Rubin RJ (1982) Five year survival in patients with carcinoma of the rectum treated by electrocoagulation. Am J Surg 143: 127PubMedGoogle Scholar
  80. 5.
    Fritsch A, Seidl W, Walzel C (1982) Palliative and adjunctive measures in rectal cancer. World J Surg 6: 569PubMedGoogle Scholar
  81. 6.
    de Graaf PW, Roussel JG, Gortzak E (1985) Early stage rectal cancer: electrofulguration in comparison to abdominoperineal exstirpation or low-anterior resection. J Surg Oncol 29: 123PubMedGoogle Scholar
  82. 7.
    Kurz KR, Reid Pitts W, Speer D (1988) Palliation of carcinoma of the rectum and pararectum using the urologic rectoscope. Surg Gynecol Obstet 166: 60PubMedGoogle Scholar
  83. 8.
    Mathus-Vliegen EMH, Tytgat GNJ (1986) Laser ablation and palliation in colorectal malignancy: results of a multicenter inquiry. Gastrointest Endosc 32: 393PubMedGoogle Scholar
  84. 9.
    Pichlmaier H, Schildberg FW (1989) Thoracic surgery. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  85. 10.
    Riemann JF, Mas R, Ginsbach Ch (1988) Palliative Lasertherapie fortgeschrittener Rektumkarzinome. Dtsch Med Wochenschr 113: 1057PubMedGoogle Scholar
  86. 11.
    Salvati EP, Rubin RJ, Eisenstat TE (1988) Electrocoagulation of selected carcinoma of the rectum. Surg Gynecol Obstet 166: 393PubMedGoogle Scholar
  87. 12.
    Weese JL, Bruskewitz RC (1984) Endoscopic transrectal resection of rectal carcinomas using the urologic rectoscope. Dis Colon Rectum 27: 123PubMedGoogle Scholar
  88. 1.
    Bader M, Dittler HJ, Ultsch B, Ries G, Siewert JR (1986) Palliative treatment of malignant stenosis of the upper gastrointestinal tract using a combination of laser and afterloading therapy. Endoscopy 18: 27–31PubMedGoogle Scholar
  89. 2.
    Cox J, Bennett JR (1987) Light at the end of the tunnel? Palliation for oesophageal carcinoma. Gut 28: 781–785PubMedGoogle Scholar
  90. 3.
    Dumon JR, Reboud E, Garbe L, Aucomte F, Meric B (1982) Treatment of tracheobronchial lesions by laser photoresection. Chest 81: 278–284PubMedGoogle Scholar
  91. 4.
    Dumon JF, Bourecerean J, Meric B, Jahjah F, Aucomte F, Dupin B (1983) Report of 100 Laser endobronchial resections. In: Joffe SN, Muckerheide MC, Goldman L (eds) Neodymium-YAG laser in medicine and surgery. Elsevier, New York, pp 59–69Google Scholar
  92. 5.
    Dumon JR, Shapshay S, Bourecerean J, Cavaliere S, Meric B, Garbi N et al (1984) Neodymium: YAG laser in bronchology. Chest 86: 163–168PubMedGoogle Scholar
  93. 6.
    Eichenhorn MS, Kvale PA, Miks VM, Seydel HG, Horowitz B, Radke JR (1986) Initial combination therapy with YAG Laser photoresection and irradiation for inoperable non-small cell carcinoma of the lung. Chest 89: 782–785PubMedGoogle Scholar
  94. 7.
    Einstein A (1917) Zur Quantentheorie der Strahlung. Phys Z 18: 121Google Scholar
  95. 8.
    Ell Ch, Riemann JF, Lux G, Demling L (1986) Palliative laser treatment of malignant stenoses in the upper gastrointestinal tract. Endoscopy 18: 21–26PubMedGoogle Scholar
  96. 9.
    Fleischer D, Sivak M (1983) Recurrent gastric adenocarcinoma treated by endoscopic Nd:YAG laser therapy. Gastrointest Endosc 29: 161Google Scholar
  97. 10.
    Fleischer D, Kessler F, Hage O (1982) Endoscopic Nd:Y AG Laser therapy for carcinoma of the esophagus: A new palliative approach. Am J Surg 143: 280PubMedGoogle Scholar
  98. 11.
    Gensic JE, Marcos HM, Uitert LG (1964) Laser oscillations in Nd-doped yttrium aluminium, yttrium gallium and gadolinium garnet. Appl Phys Lett 4: 182–184Google Scholar
  99. 12.
    Goodale RL, Okada A, Gozalez R (1970) Rapid endoscopic control of bleeding gastric erosions by laser radiation. Arch Surg 101: 211PubMedGoogle Scholar
  100. 13.
    Kahida EF, Gordon FI, Miller RC (1965) Continuous duty argon ion lasers. IEEE J Quantum Electron I: 273–279Google Scholar
  101. 14.
    Kiefhaber P (1984) Indikationen für die endoskopische Verwendung des Lasers im Gastrointestinaltrakt. Münch Med Wschr 5: 103Google Scholar
  102. 15.
    Kiefhaber P, Nath G, Moritz K (1977) Endoscopical control of massive gastrointestinal hemorrhage by irradiation with a high-power Neodymium-Yag laser. Progr Surg 15: 140–150Google Scholar
  103. 16.
    Kiefhaber P, Moritz K, Heldwein W, Lehnert P, Weidinger P (1979) Endoskopische Blutstillung blutender Ösophagus- und Magenvarizen mit einem Hochleistungs Neodym YAG Laser. In: Demling L, Rösch W (Hrsg) Operative Endoskopie. Acrm, BerlinGoogle Scholar
  104. 17.
    Maiman TH (1960) Stimulated optical radiation in ruby. Nature 187: 493–494Google Scholar
  105. 18.
    Nath G, Gorisch W, Kiefhaber P (1973) First laser endoscopy via a fiberoptic transmission system. Endoscopy 5: 208–213Google Scholar
  106. 19.
    Nishioka NS, Jacques SL, Richter JM, Anderson RR (1988) Reflection and transmission of laser light from the esophagus: The influence of incident angle. Gastroenterology 94: 1180–1185PubMedGoogle Scholar
  107. 20.
    Unger M, Atkinson G, William MD (1983) Nd:YAG Laser applications in pulmonary and endobronchiallesions. In: Joffe SN, Muckerheide MC, Goldman L (eds) Neodymium-YAG laser in medicine and surgery. Elsevier, New York, pp 71–81Google Scholar
  108. 21.
    Van Gossum A, Adler M, Des Marez B, Cemachovic I, Cremer M (1987) Endoscopic Nd-YAG laser therapy. A safe and effective form of palliative treatment for rectal adenocarcinoma. Acta Gastroenterol Belg 50: 218–224PubMedGoogle Scholar
  109. 22.
    Wolfe WG, Cole PH, Sabiston DC (1984) Experimental and clinical use of the YAG laser in the management of pulmonary neoplasms. Am Surg 199: 526–531Google Scholar
  110. 23.
    Wolfe WG, Sabiston DC, Durham NC (1986) Management of benign and malignant lesions of the trachea and bronchi with the neodymium-yttrium-aluminium-garnet laser. J Thorac Cardiovasc Surg 91 : 40–45PubMedGoogle Scholar
  111. 1.
    Ablin R (ed) (1980) Handbook of cryosurgery. Dekker, New York BaselGoogle Scholar
  112. 2.
    Chilla R, Opiatz M (1982) Die Bedeutung der Kryotherapie für die Behandlung benigner und maligner Mundschleimhautveränderungen. Rhinol Oto 161: 445Google Scholar
  113. 3.
    Cooper IS, Lee AS (1961) Cryostatic congelation: a system for producing a limited controlled region of cooling or freezing of biological tissues. J Nerv Ment Dis 133: 259PubMedGoogle Scholar
  114. 4.
    Cooper IS, Hirose T (1966) Application of cryogenic surgery to resection of parenchymal organs. J Med 274: 15Google Scholar
  115. 5.
    Fritsch A, Seidl W, Walzel C, Moser K, Schiessel R (1982) Palliative and adjunctive measures in rectal cancer. World J Surg 6: 569PubMedGoogle Scholar
  116. 6.
    Gage AA (1984) Cryosurgery for cancer. Compr Ther 10 (1): 61PubMedGoogle Scholar
  117. 7.
    Heberer G, Deneke H, Demmel N, Wisching R (1987) Local procedures in the management of rectal cancer. World J Surg 11: 499PubMedGoogle Scholar
  118. 8.
    Helpap B (1980) Der kryochirurgische Eingriff und seine Folgen. Thieme, Stuttgart New YorkGoogle Scholar
  119. 9.
    Kogel H, Willmen HR, Pichlmaier H, Junginger Th (1983) Kryotherapie des Mastdarmkrebses. Chir Praxis 31: 633Google Scholar
  120. 10.
    Kogel H, Grundmann R, Fohlmeister I, Pichlmaier H (1985) Zur Kryotherapie des Rektumkarzinoms. Zentralbl Chir 110: 147PubMedGoogle Scholar
  121. 11.
    Langer S (1981) Kryo-Chirurgie. Langenbecks Arch Chir 355: 475PubMedGoogle Scholar
  122. 12.
    Peitsch W, Schafmeyer A, Lange W (1988) Die Behandlung inoperabler Rektumkarzinome durch Kryochirurgie. Dtsch Ärztebl 85: 581Google Scholar
  123. 13.
    Reifferscheid M, Langer S (1980) Der Mastdarmkrebs. Schließmuskelerhaltende Therapieverfahren und ihre Indikationsgrenzen. Thieme, Stuttgart New YorkGoogle Scholar
  124. 14.
    Sommer J, Renziehausen K, Neuhauser H, Neuhauser M, Hecker J (1986) Möglichkeiten und Grenzen der Kryochirurgie des Vulvakarzinoms - 12jährige Therapieergebnisse. Zentralbl Gynäkol 108: 649PubMedGoogle Scholar
  125. 15.
    Theiß R, Schmidt KH, Bueß G, Junginger Th (1985) Kryochirurgie beim inoperablen Rektumkarzinom. Zentralbl Chir 110: 142PubMedGoogle Scholar
  126. 16.
    Walzel C (1978) Der heutige Stand der Kryochirurgie. Chirurg 49: 202PubMedGoogle Scholar
  127. 17.
    Walzel C (1980) Kryochirurgie des Rektumkarzinoms. Krebsgeschehen, KIin Prax Onkol 3: 60Google Scholar
  128. 18.
    Zacarian SA (1985) Complications, indications and contraindications. Cryosurgery for skin cancer and cutaneous disorders. Mosby, St Louis, pp 283–297Google Scholar
  129. 1.
    Bader M, Dittler HJ, Ries G, Ultsch B, Lehr L, Siewert JR (1985) Endokavitäre Strahlentherapie in Afterloading-Technik bei malign en Stenosen des oberen Gastrointestinaltraktes und der Gallenwege. Leber Magen Darm 15: 247–255PubMedGoogle Scholar
  130. 2.
    Heilmann H-P (Hrsg) (1985) Palliative Therapie. Zuckschwerdt, Munchen Bern Wien (Aktuelle Onkologie, Bd 23)Google Scholar
  131. 3.
    Kagan AR (1987) Radiotherapy management of metastasis. Refresher course. 29th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Boston/Mass. 18.-23.X.1987Google Scholar
  132. 4.
    Kagan AR (1987) Radiotherapeutic management of the patient for palliation. In: Perez CA, Brady LW (eds) Radiation oncology. Lippincott, PhiladelphiaGoogle Scholar
  133. 5.
    Kagan AR (1988) Dose-time relationship in the palliation of metastasis to liver, lung, brain and bone by radiation. Front Radiat Ther Oncol 22: 165–176PubMedGoogle Scholar
  134. 6.
    Montague ED, De1clos L (1980) Palliative radiotherapy in the management of metastatic disease. In: Fletcher GH (ed) Textbook of radiotherapy, 3rd edn. Lea & Febiger, Philadelphia, pp 943–948Google Scholar
  135. 7.
    Richter MP, Coia LR (1985) Palliative radiation therapy. Semin Oncol 12: 375–383PubMedGoogle Scholar
  136. 8.
    Rubin Ph, Salazar O, Zagars G, Constine LS, Keys H, Poulter CA, van Ess JD (1985) Systemic hemibody irradiation for overt and occult metastases. Cancer 55: 2210–2221PubMedGoogle Scholar
  137. 9.
    Tepper JE, Wood WC, Cohen AM, Shipley WU, Orlow E, Hedberg SE, Warshaw AL et al. (1985) Intraoperative radiation therapy. In: deVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 226–242Google Scholar
  138. 1.
    Aigner KR (1987) Isolated liver perfusion - pharmacokinetic considerations and clinical results. In: Aigner KR, Patt YZ (eds) Regional cancer treatment contributions to oncology. Karger, BaselGoogle Scholar
  139. 2.
    Austin EH, Wayne FM (1979) The treatment of recurrent malignant pleural effusion. Ann Thorac Surg 28: 190–203PubMedGoogle Scholar
  140. 3.
    Beahrs OH, Sanfelippo PM (1971) Prognostic factors in carcinoma of the colon and rectum. Cancer 28: 213–217PubMedGoogle Scholar
  141. 4.
    Bedikian AY (1983) Regional and systemic chemotherapy for advanced colorectal cancer - a review. Dis Colon Rectum 26: 327–332PubMedGoogle Scholar
  142. 5.
    Beecham J, Blessing J, Creasman W, Hatch K (1987) Tamoxifen is effective as second line therapy for certain patients with advanced, chemotherapy-resistant epithelial ovarian cancer: a gynecologic oncology group study for 105 patients. Proc Am Soc Clin Oncol 7: 522Google Scholar
  143. 6.
    Beretta G, Labianca R, Locatell C et al. (1985) Epirubicin evaluation phase II-III studies at OSCB-Milan. Proc Am Soc Clin Oncol 4: 246Google Scholar
  144. 7.
    Bitrann JD, Desser RK, Kozloff MF et al. (1979) Treatment of metastatic adenocarcinoma of the pancreas with 5-fluorouracil, adriamycin and mitomycin C (FAM). Cancer Treat Rep 63: 2049–2051Google Scholar
  145. 8.
    Blumenreich MS, Yagoda A, Natale RB, Watson RC (1982) Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50: 435–441PubMedGoogle Scholar
  146. 9.
    Brandes U, Israels LG (1982) Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednison. Cancer Treat Rep 66: 1413–1415PubMedGoogle Scholar
  147. 10.
    Brenner DE (1986) Intraperitoneal chemotherapy: a review. J Clin Oncol 4: 1135–1147PubMedGoogle Scholar
  148. 11.
    Brunner KW (1987) Palliative Tumor-Chemotherapie und Lebensqualität: was ist optimal? Schweiz Med Wochenschr 117: 688–692PubMedGoogle Scholar
  149. 12.
    Buroker TR (1985) A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil in colorectal carcinoma. J Clin Oncol 3: 1624–1631PubMedGoogle Scholar
  150. 13.
    Cullinan S, Moertel C, Fleming T et al. (1984) A randomized comparison of 5-FU alone (F), 5-FU + adriamycin (FA) and 5-FU + adriamycin + mitomycin-CX (FAM) in gastric and pancreatic cancer. Proc Am Soc Clin Oncol 3: 137Google Scholar
  151. 14.
    Cummings B, Keane T, Thomas G et al. (1984) Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. Cancer 65: 2062–2068Google Scholar
  152. 15.
    DeHaes JCM, von Kippenberg CE (1985) The quality of life of cancer patients. A review of the literature. Soc Sci Med 20: 809–817PubMedGoogle Scholar
  153. 16.
    DeVita VT (1986) Dose-response is alive and well. J Clin Oncol 4: 1157–1158Google Scholar
  154. 17.
    Ehrlichman C, Fine S, Wong A, Elhakim T (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475Google Scholar
  155. 18.
    Gastrointestinal Tumor Study Group (1982) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53: 13–17Google Scholar
  156. 19.
    Gralla RJ, Raphael BG, Young CW (1979) Phase II evaluation of vindesine in patients with nons mall cancer of the lung. Cancer Treat Rep 63: 1343–1346PubMedGoogle Scholar
  157. 20.
    Gelber RD, Goldhirsch A (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4: 197–201Google Scholar
  158. 21.
    Gyves JW, Ensminger WD, Stetson P et al. (1984) Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin Pharmacol Ther 35: 83–89PubMedGoogle Scholar
  159. 22.
    Hakes TB, Chalas E, Saigo P, Geller N, Lewis JL (1987) Randomized prospective trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy: 5 versus 10 cycles in stage III & IV ovarian carcinoma. Proc Am Soc Clin Oncol 6: 456Google Scholar
  160. 23.
    Hartlapp JH, Hollunder A (1987) Polychemotherapy for the treatment of extensive stage small cell lung cancer (SCLC). Proc Eur Conf Clin Oncol Cancer Nurs 4: 88Google Scholar
  161. 24.
    Hohn D, Stagg R, Friedman M, Ignoffo R, Rayner A, Hannigan J, Lewis B (1987) The NCOG randomized trial of intravenous vs. hepatic arterial FUDR for colorectal cancer metastatic to the liver. Proc Am Soc Clin Oncol 6: 333Google Scholar
  162. 25.
    Hortobagyi GN, Bodey GP, Buzdar AU et al. (1987) Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5: 354–364PubMedGoogle Scholar
  163. 26.
    Howell SB, Chu BB, Wung WE et al. (1981) Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67: 1161–1170PubMedGoogle Scholar
  164. 27.
    Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162–1170PubMedGoogle Scholar
  165. 28.
    Jenkins J, Sugarbaker P, Gianola F et al. (1982) Technical considerations in the use of intra peritoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet 154: 858–864PubMedGoogle Scholar
  166. 29.
    Jarakousis CP (1982) Prednimustin in advanced soft tissue sarcomas. Cancer Treat Rep 66: 201–202Google Scholar
  167. 30.
    Kelsen D (1984) Chemotherapy of esophageal cancer. Semin Oncoll 1: 159–169Google Scholar
  168. 31.
    Kelsen D (1985) Chemotherapy of esophageal cancer. Eur J Cancer Clin Oncol 21: 5–7PubMedGoogle Scholar
  169. 32.
    Klein HO, Wickramanayake PD, Farrokh G-R(1986) 5-fluorouracil (5-FU), adriamycin (ADM) and methotrexat (MTX) - a combination protocol (FAMTX) for metastasized stomach cancer. Proc Am Soc Clin Oncol 84: 825Google Scholar
  170. 33.
    Kolaric K (1983) Studies with epirubicin in gastric cancer. In: Bonadonna G (ed) Advances in anthracycline chemotherapy: epirubicin. Masson, Milan, pp 111–118Google Scholar
  171. 34.
    Kreuser ED (1985) Maligne Pleuraergüsse: Pathophysiologie, Diagnostik und Therapie. Dtsch Med Wochenschr 110: 1381–1386PubMedGoogle Scholar
  172. 35.
    Krook JE, O’Connell MJ, Wieand HS (1988) Surgical adjuvant therapy of gastric cancer with doxorubicin and 5-fluorouracil. A joint Mayo Clinic / North Central Cancer Treatment Group study. Proc Am Soc Clin Oncol 7: 93Google Scholar
  173. 36.
    Kühnle H (1986) A phase II study of etoposide in advanced ovarian cancer with primary and secondary resistance to high dose cisplatin. Proc Am Assoc Cancer Res 27: 761Google Scholar
  174. 37.
    Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 193–217Google Scholar
  175. 38.
    Lober J, Mouridsen HT, Christiansen IE et al. (1983) A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer. Cancer 52: 1570–1575PubMedGoogle Scholar
  176. 39.
    Machover D, Schwarzenberg L, Goldschmidt E (1982) Treatment of advanced colorectal and gastric adenocarcinoma with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 66: 1803–1807PubMedGoogle Scholar
  177. 40.
    Machover D, Goldschmidt E, Chollet P et al. (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685–696PubMedGoogle Scholar
  178. 41.
    Mallinson CN (1980) Chemotherapy in pancreatic cancer: results of a controlled, prospective, multicenter trials. Br Med J 281: 1589–1591PubMedGoogle Scholar
  179. 42.
    Malt RA (1983) Treatment of pancreatic cancer. JAMA 250: 1433–1443PubMedGoogle Scholar
  180. 43.
    McDonald JS, Schein PS, Woolley PV (1980) 5-fluorouracil, doxorubicin, mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533Google Scholar
  181. 44.
    McKelvey EM, Gottlieb JA, Wilson HE (1976) Hydroxydaunomycin combination chemotherapy in malignant lymphoma. Cancer 38: 1481–1488Google Scholar
  182. 45.
    Meyers FJ, Lewis B, Mitchell E et al. (1985) Phase II-trial of 4-epidoxorubicinin advanced colorectal carcinoma: a Northern California Oncology Group study. Cancer Treat Rep 69: 143–144PubMedGoogle Scholar
  183. 46.
    Moertel CG (1984) Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1: 727–740Google Scholar
  184. 47.
    Myers C (1984) The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncoll 1: 275–284Google Scholar
  185. 48.
    Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW (1981) Methotrexate: an active drug in bladder cancer. Cancer 47: 1246–1250PubMedGoogle Scholar
  186. 49.
    O’Connell MJ (1985) Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3: 1032–1039PubMedGoogle Scholar
  187. 50.
    Petrelli N, Stablein D, Bruckner H et al. (1988) A prospective randomized phase III trial of 5-fluorouracil (5-FU) versus 5-FU + high dose leucovorin (HDCF) versus 5-FU + low dose leucovorin (LDCF) in patients with metastatic colorectal adenocarcinoma. A report of the gastrointestinal tumor study group. Proc Am Soc Clin Oncol 7: 94Google Scholar
  188. 51.
    Pfeifle CE, Howell SB, Markman M, Lucas W (1984) Totally implantable system for peritoneal access. J Clin Oncol 2: 1277–1280PubMedGoogle Scholar
  189. 52.
    Rhomberg WU, Mesche E (1981) Vindesine in the treatment of advanced solid tumors. Experience with a twice weekly schedule. In: Brade W, Nagel GA, Seeber S (eds) Proceedings of the International Vinca Alkaloid Symposium - Vindesin. Karger, Basel, pp 222–226Google Scholar
  190. 53.
    Ross MB, Buzdar AV, Smith TL et al. (1985) Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55: 341–346PubMedGoogle Scholar
  191. 54.
    Schein PS (1985) The role of chemotherapy in the management of gastric and pancreatic carcinomas. Semin Onco1 12: 49–60Google Scholar
  192. 55.
    Sikic BI, Ballon SC, Suey L et al. (1986) Activity of high-dose megestrol acetate in patients with epithelial ovarian cancers refractory to chemotherapy. A phase II study of the Northern California Oncology Group. Proc Am Soc Clin Oncol 5: 477Google Scholar
  193. 56.
    Speyer JL, Collins JM, Dedrick RL et al. (1984) Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40: 567–572Google Scholar
  194. 57.
    Tapazoglou E, Kish J, Ensley J, Al-Sarraf M (1986) The activity of a single-agent-5-fluorouracil infusion in advanced and recurrent head and neck cancer. Cancer 57: 1105–1109PubMedGoogle Scholar
  195. 58.
    Ten Bokkel Huinink WW, Dubbelman R, Aartsen A et al. (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12 [Suppl 4]: 43–46PubMedGoogle Scholar
  196. 59.
    Valone FH, Drakes T, Flam M, Hannigan J (1988) Randomized trial of 5-FU vs.leucovorin plus 5-FU vs. sequential methotrexate, 5-FU, leucovorin in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 7: 95Google Scholar
  197. 60.
    Weiß J, Schmoll HJ (1984) Aminogluthetimid beim metastasierten Nebennierenkarzinom: Hochdosisbehandlung und Tachyphylaxie. In: Nagel GA, Schmidt-Matthiesen H, Drees N (Hrsg) Aminogluthetimid: ein Antiostrogen mit Aromatasehemmung. Zuckerschwerdt, München, S 152–156Google Scholar
  198. 61.
    Wils J, Bleiberg H, Blijham G et al. (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Onco 121: 191–194Google Scholar
  199. 62.
    Zinser JW, Hortobagyi N, Buzdar A, Smith TL, Fraschini G (1987) Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773–782PubMedGoogle Scholar
  200. 1.
    Aigner KR, Walther H, Tonn JC, Link KH, Schoch P, Schwemmle K (1984) Die isoJierte Leberperfusion bei fortgeschrittenen Metastasen kolorektaler Carcinome. Onkologie 7: 13PubMedGoogle Scholar
  201. 2.
    Balch CM, Urist MM (1984) Intraarterielle Chemotherapie mit einer implantierbaren Infusionspumpe bei Lebermetastasen colorectaler Carcinome und Hepatomen. Chirurg 55: 485PubMedGoogle Scholar
  202. 3.
    Bengtsson G, Carlsson G, Hafström L, Jönsson PE (1981) Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141 : 586PubMedGoogle Scholar
  203. 4.
    Cohen AM, Kaufmann SO, Wood WC (1985) Treatment of colorectal cancer hepatic metastases by hepatic artery chemotherapy. Dis Colon Rectum 28: 389PubMedGoogle Scholar
  204. 5.
    Creech O, Krementz ET, Ryan RF (1958) Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 148: 616PubMedGoogle Scholar
  205. 6.
    Ghussen F, Isselhard W (1984) The limit of hyperthermic strain on skeletal muscle tissue during regional perfusion. Res Exp Med 184: 115Google Scholar
  206. 7.
    Ghussen F, Nagel K, Isselhard W, Marx G, Wellart A, Müller EW (1982) Ein neues Verfahren zur isolierten regionalen Leberperfusion in vivo. Langenbecks Arch Chir 356: 251PubMedGoogle Scholar
  207. 8.
    Hottenrott C, Nagel K, Lorenz M (1986) Regionale Chemotherapie der Leber und Extremitäten. Standortbestimmung. Kehrer, FreiburgGoogle Scholar
  208. 9.
    Huber R, Helling HJ, Groth W, Pichlmaier H (1990) 10 Jahre hypertherme Extremitätenperfusion - Ein Erfahrungsbericht. Zentralbl Chir 115: 578Google Scholar
  209. 10.
    Jacobs JU, Fexner JM, Scott HW (1961) Selective isolated perfusion of the right or left lung. J Thorac Cardiovasc Surg 42: 546PubMedGoogle Scholar
  210. 11.
    Johnston MR, Minchin R, Shull JH, Thenot JP, Mc Manns BM, Terril R, Boyd MR (1983) Isolated lung perfusion with adriamycin. Cancer 52: 404PubMedGoogle Scholar
  211. 12.
    Krementz ET (1986) Regional perfusion. Current sophistication, what next? Cancer 57: 416PubMedGoogle Scholar
  212. 13.
    Kemeny MM, Goldberg D, Beatty D et al. (1986) Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 57: 492PubMedGoogle Scholar
  213. 14.
    Lahr CJ, Soong SJ, Cloud G, Smith J, Urist MM, Balch CM (1983) A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol 1: 720PubMedGoogle Scholar
  214. 15.
    Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E (1984) Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53: 1336PubMedGoogle Scholar
  215. 16.
    Pierpont H, Blades B (1960) Lung perfusion with chemotherapeutic agents. J Thorac Cardiovasc Surg 39: 159PubMedGoogle Scholar
  216. 17.
    Schraffordt-Koops H, Beekhuis H, Oldhoff J, Osterhuis JW, van der Ploog E, Vermey A (1981) Local recurrence and survival in patients with stage I malignant melanoma of the extremities after regional perfusion. Cancer 48: 1952PubMedGoogle Scholar
  217. 18.
    Shepard KV, Levin B, Karl RC, Faintuch J, DuBrow RA, Hagle M, Cooper RM, Beschorner J, Stablein D (1985) Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 3: 161PubMedGoogle Scholar
  218. 19.
    Shingleton WW, Parker RY, Mahaley S (1961) Abdominal perfusion of cancer chemotherapy with hypothermia and hyperthermia. Surgery 50: 260Google Scholar
  219. 20.
    Stehlin JS (1969) Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 129: 305PubMedGoogle Scholar
  220. 21.
    Sugarbaker P, Chang AE, Schneider PhD, Simpson C, Culnane M, Steinberg SM (1988) A prospective randomized trial of regional versus systemic continuous 5-fluorodoxyuridine chemotherapy in the treatment of colorectalliver metastases. Workshop: Progress in Regional Chemotherapy I Wien, 3.-5. November.Google Scholar
  221. 22.
    Woodhall B, Hall K, Mahaley S, Jackson J (1959) Chemotherapy of brain cancer. Experimental and clinical studies in localized hypothermic brain perfusion. Ann Surg 150: 640PubMedGoogle Scholar
  222. 1.
    Alavi JB, McLean GK (1983) Hypertension with renal carcinoma. An effect of arterial embolization. Cancer 52: 169–172PubMedGoogle Scholar
  223. 2.
    Allison DJ, Jordan H, Hennessy O (1985) Therapeutic embolization of the hepatic artery: A review of 75 procedures. Lancet I: 595–599Google Scholar
  224. 3.
    Attali P, Houssin D, Roche A, Buffet C, Bismuth H, Etienne JP (1984) Hepatic arterial embolization for malignant hypercalcemia in hepatocellular carcinoma. Dig Dis Sci 29: 466–469PubMedGoogle Scholar
  225. 4.
    Basche S, Leisering W, Kachel R (1988) Die Bedeutung der Embolisationstherapie für die Prognose des Nierenzellkarzinoms. In: Schneider GH, Vogler E (Hrsg) Digitale bildgebende Verfahren. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  226. 5.
    Bechtel W, Wright KC, Wallace S, Mosier B, et al. (1986) An experimental evaluation of microcapsules for arterial chemoembolization. Radiology 161: 601–604PubMedGoogle Scholar
  227. 6.
    Berenstein A, Kricheff II (1979) Catheter and material selection for transarterial embolization: Technical considerations. Radiology 132: 619–630PubMedGoogle Scholar
  228. 7.
    Bono AV, Caresano A (1983) The role of embolization in the treatment of kidney carcinoma. Eur Uro1 9: 334–337Google Scholar
  229. 8.
    Braedel HU, Zwergel U, Knopp W (1984) Embolization of pelvic bone metastases from renal cell carcinoma. Eur Urol 10: 380–384PubMedGoogle Scholar
  230. 9.
    Carrasco Ch, Soo CS, Chuang VP, Wallace S (1983) Transcatheter management of hepatic neoplasms. Appl Radiol 12: 47–48, 50, 52–54Google Scholar
  231. 10.
    Carroll BA, Walter JF (1983) Gas in embolized tumors: An alternate hypothesis for its origin. Radiology 147: 441–444PubMedGoogle Scholar
  232. 11.
    Cataneda-Zuniga WR, Sanchez R, Amplatz K (1978) Experimental observations on short and long-term effects of arterial occlusion with ivalon. Radiology 126: 783–785Google Scholar
  233. 12.
    Cho KJ, Lunderquist A (1983) Experimental hepatic artery embolization with gelfoam powder. Invest Radiol 18: 189–193PubMedGoogle Scholar
  234. 13.
    Chuang VP, Wallace S (1981) Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 140: 51–58PubMedGoogle Scholar
  235. 14.
    Chuang VP, Wallace S (1983) Interventional approaches to hepatic tumor treatment. Semin Roentgenol 18: 127–135PubMedGoogle Scholar
  236. 15.
    Chuang VP, Wallace S, Soo CS, Charnsangavej C, Bowers T (1982) Therapeutic ivalon embolization of hepatic tumors. AJR 138: 289–294PubMedGoogle Scholar
  237. 16.
    Clouse ME, Lee RGL, Duszlak EJ, Lokich JJ et al. (1983) Peripheral hepatic artery embolization for primary and secondary hepatic neoplasms. Radiology 147: 407–411PubMedGoogle Scholar
  238. 17.
    Coldwell D, Roth H, Mortimer J, Press O, Nance D, Harley J, Goldman M (1988) Alternation in liver function tests after hepatic arterial embolization. Proc Annu Meet Am Soc Clin Oncol 7: A422Google Scholar
  239. 18.
    Coldwell DM, Hottenstein DW, Ricci JA, Wengert PA (1985) Emphysematous cholecystitis as a complication of hepatic arterial embolization. Cardiovasc Intervent Radiol 8: 36–38PubMedGoogle Scholar
  240. 19.
    Cox GG, Lee KR, Price HI, Gunter K, Noble MJ, Mebust WK (1982) Colonic infarction following ethanol embolization of renal-cell carcinoma. Radiology 145: 343–345PubMedGoogle Scholar
  241. 20.
    Doppman JL, Girton M, Vermess M (1982) The risk of hepatic artery embolization in the presence of obstructive jaundice. Radiology 143: 37–43PubMedGoogle Scholar
  242. 21.
    Doppman JL, Girton ME (1984) Bile duct scarring following ethanol embolization of the hepatic artery: An experimental study in monkeys. Radiology 152: 621–626PubMedGoogle Scholar
  243. 22.
    Ekelund L, Karp W, Mansson W, Olsson AM (1981) Palliative embolization of renal tumors: follow-up of 19 cases. Urol Radiol 3: 13–18PubMedGoogle Scholar
  244. 23.
    Furui S, Otomo K, Itai Y, lio M (1984) Hepatocellular carcinoma treated by trans catheter arterial embolization: Progress evaluated by computed tomographie. Radiology 150: 773–778PubMedGoogle Scholar
  245. 24.
    Gianturco C, Anderson JH, Wallace S (1975) Mechanical devices for arterial occlusion. AJR 124: 428–435Google Scholar
  246. 25.
    Goldman ML, Philip PK, Sarrafizadeh MS (1984) Bucrylate, a liquid tissue adhesive for traoscatheter embolization. Appl Radiol: 89–94Google Scholar
  247. 26.
    Jaschke W, Hoevels J (1988) Control of hepatic tumor hemorrhage by transcatheter embolization with Ethibloc. Acta Radiol 29: 15–19PubMedGoogle Scholar
  248. 27.
    Junyuan G, Zhicheng H, Pengcheng L, Daoyu H (1987) Intraarterielle Chemotherapie und Embolisierung der Arteria hepatica bei primären Lebercarcinomen. Röntgenpraxis 40: 211–214Google Scholar
  249. 28.
    Kato T, Nemoto R, Mori H, Takahashi M et al. (1981) Arterial chemoembolization with mitomycin C microcapsules in the treatment of primary or secondary carcinoma of the kidney, liver, bone and intrapelvic organs. Cancer 48: 674–680PubMedGoogle Scholar
  250. 29.
    Kauffmann GW, Rohrbach R, Richter G, Rossweiler J, Sommerkamp H (1984) Nierentumorembolisation. Fortschritte, Erfahrungen und Komplikationen. Urologe 23: 109–116PubMedGoogle Scholar
  251. 30.
    Kaufmann G, Richter G (1988) Embolisationsmaterialien. In: Günther R, Thelen M (Hrsg) Interventionelle Radiologie. Thieme, StuttgartGoogle Scholar
  252. 31.
    Kaufmann G, Richter G (1988) Embolisation der Niere. In: Günther R, Thelen M (Hrsg) Interventionelle Radiologie. Thieme, StuttgartGoogle Scholar
  253. 32.
    Kim Th, Chuang V, Ricketts R, Zaatari G et al. (1986) Improved surgical resectability of childhood hepatic malignancies by primary transcatheter embolization. Proc Am Soc Clin Onool 5: 203Google Scholar
  254. 33.
    Klose KJ, Thelen M, Günther R, Wanek R (1981) Transcatheter embolization in pelvic malignancy. A summary of 26 cases. Ann Radiol 24: 390–393PubMedGoogle Scholar
  255. 34.
    Lammer J, Justich E, Schreyer H, Ebner F (1983) Therapeutische Embolisation mit Polyvinylalkohol (Ivalon). Klinische Erfahrungen. Röntgenblätter 36: 152–157Google Scholar
  256. 35.
    Lammer J, Justich E, Schreyer H, Pettek R (1985) Complications of renal tumor embolization. Cardiovasc Intervent Radiol 8: 31–35PubMedGoogle Scholar
  257. 36.
    Lang EK (1984) Transcatheter embolization of renal tumors with 1–124 particies. Digitale Bilddiagn 4: 165–170PubMedGoogle Scholar
  258. 37.
    Lasjaunias P (1980) Nasopharyngeal angiofibromas: Hazards of embolization. Radiology 136: 119–123PubMedGoogle Scholar
  259. 38.
    Löhr E, Ross S (1985) Embolisationstherapie von Nierentumoren-Erfahrungen an einem Krankengut von 60 Patienten. Radiologe 25: 354–358PubMedGoogle Scholar
  260. 39.
    Löhr E, Schmitt-Neuerburg P, Heckemann R (1985) Embolisationstherapie von primären Weichteiltumoren und metastatischen Raumforderungen im Beckenbereich. Radiologe 25: 359–363PubMedGoogle Scholar
  261. 40.
    Martensson H, Nobin A, Bengmark S, Lunderquist A, Owman T, Sanden G (1984) Embolization of the liver in the management of metastatic carcinoid tumors. J Surg Onco 127: 152–158Google Scholar
  262. 41.
    Marx FJ, Chaussy C, Moser E (1982) Grenzen und Gefahren der palliativen Embolisation inoperabler Nierentumoren. Urologe (Aus. A) 21: 206–210Google Scholar
  263. 42.
    Mathias K, Löffler T, Hoffmann G, Hausamen T (1986) Radiologischer Beitrag zur Behandlung primärer und sekundärer Lebertumoren. Radiologe 26: 129–136PubMedGoogle Scholar
  264. 43.
    Mazer MJ, Baltaxe HA, Wolf GL (1981) Therapeutic embolization of the renal artery with Gianturco coils: limitations and technical pitfalls. Radiology 138: 37–46PubMedGoogle Scholar
  265. 44.
    Milewski JB, Malewski AW, Malanowska S, Borkowski A, Skowronski IA, Tomankiewicz Z, Sawicka E (1981) Spinal cord damage as a complication of renal artery embolization in patients with renal carcinoma. Int Urol Nephrol 13: 221–229PubMedGoogle Scholar
  266. 45.
    Mitty HA, Warner RRP, Newman LH, Train JS et al. (1985) Control of carcinoid syndrome with hepatic artery embolization. Radiology 155: 623–626PubMedGoogle Scholar
  267. 46.
    Nakamura H, Hashimoto T, Oi H, Sawada S (1987) Hepatic embolization through periportal collaterals: Balloon occlusion technique. AJR 148: 626–628PubMedGoogle Scholar
  268. 47.
    Nakamura H, Hashimoto T, Oi H, Sawada S (1988) Iodized oil in the portal vein alter arterial embolization. Radiology 167: 415–417PubMedGoogle Scholar
  269. 48.
    Nakao N, Miura K, Takahashi H, Ohnishi M et al. (1986) Hepatocellular carcinoma: Combined hepatic, arterial, and portal venous embolization. Radiology 161: 303–307PubMedGoogle Scholar
  270. 49.
    Nemoto R, Kato T, Iwata K, Mori H, Takahashani M (1981) Evaluation of therapeutic arterial embolization in renal cell carcinoma using microencapsulated mitomycin C. Urology 17: 315–319PubMedGoogle Scholar
  271. 50.
    Ohishi H, Uchida H, Yoshimura H, Ohue S et al. (1985) Hepatocellular carcinoma detected by iodized oil. Radiology 154: 25–29PubMedGoogle Scholar
  272. 51.
    Patt YZ, Chuang VP, Wallace S, Hersh EM et al. (1981) The palliative role of hepatic arterial infusion and arterial occlusion in colorectal carcinoma metastatic to the liver. Lancet: 349–350Google Scholar
  273. 52.
    Pfeifer KJ, Eibl-Eibesfeldt B, Huber RM, Kenn RW, Mangel E, Mayr B (1988) Mikroembolisation von Lebermetastasen. In: Schneider GH, Vogler E (Hrsg) Digitale bildgebende Verfahren. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  274. 53.
    Powell-Tuck J, Mcivor J, Reynolds KW, Murray-Lyon IM (1984) Prediction of early death after therapeutic hepatic arterial embolization. Br Med J (Clin Res) 288: 1257–1259Google Scholar
  275. 54.
    Quinn MF, Lundell CJ, Daniels JR, Vegh GB, Engelson ET (1988) Transpancreatic catheterization of the right hepatic artery for chemoembolization using a new infusion system. Cathet Cardiovasc Diagn 14: 115–117PubMedGoogle Scholar
  276. 55.
    Remy J, Arnaud A, Fardou H, Giraud R, Voisin C (1977) Treatment of hemoptysis by embolization of bronchial arteris. Radiology 122: 33–37PubMedGoogle Scholar
  277. 56.
    Richter GM, Kauffmann GW, Wimmer B (1985) Die kapilläre Embolisation des blutenden Nierentumors. Ein ungewöhnlicher Fallbericht. Radiologe 25: 364–370PubMedGoogle Scholar
  278. 57.
    Schild H (1988) Embolisation der Leber. In: Gunther R, Thelen M (Hrsg) Interventionelle Radiologie. Thieme, StuttgartGoogle Scholar
  279. 58.
    Schoenemann B (1981) Anomalien der Arterien im Oberbauch und ihre chirurgische Relevanz. Inaugural-Dissertation, Med. Fakultät, Universitat KölnGoogle Scholar
  280. 59.
    Schultheis KH (1985) Embolisation - Chemoembolisation. Beitr Onkol 21: 201–228Google Scholar
  281. 60.
    Seifart W, Waigand J, Booss HJ, Slisow W, Uhlig F (1986) Chemoembolisation der A. hepatica kombiniert mit intraportaler Zytostatikum-Infusion. Ein neues Konzept für die regionale Chemotherapie von Lebermetastasen. Arch Geschwulstforsch 56: 445–450PubMedGoogle Scholar
  282. 61.
    Stoesslein F, Ditscherlein G, Romaniuk PA (1982) Experimental studies on new liquid embolization mixtures (Histoacryl-Lipiodol, Histoacryl-Panthopaque). Cardiovasc Intervent Radiol 5: 264–267PubMedGoogle Scholar
  283. 62.
    Suzuki K, Kono N, Ono A, Osuga Y et al. (1988) Transcatheter arterial chemo-embolization for humoral hypercalcemia of hepatocellular carcinoma. Gastroenterol Jpn 23: 29–36PubMedGoogle Scholar
  284. 63.
    Takayasu K, Moriyama N, Muramatsu Y, Suzuki M et al. (1984) Hepatic arterial embolization for hepatocellular carcinoma. Radiology 150: 661–665PubMedGoogle Scholar
  285. 64.
    Takayasu K, Moriyama N, Muramatsu Y, Suzuki M et al. (1984) Splenic infarction, a complication of trans catheter hepatic arterial embolization for liver malignancies. Radiology 151: 371–375PubMedGoogle Scholar
  286. 65.
    Toelle E, Cramer BM (1983) K1inische Erfahrungen mit der arteriellen Embolisation von Nierentumoren mit Äthanol. Urologe [A] 22: 208–212Google Scholar
  287. 66.
    Triller J, Schröder R (1985) Perkutane intraarterielle Infusion und Embolisation von Lebermetastasen kolorektaler Karzinome. Fortschr Röntgenstr 143: 307–315Google Scholar
  288. 67.
    Tylen U, Dah E, Fredlund P (1981) Angiography after temporary inhibition of blood flow followed by intraarterial 5-fu infusion in the treatment ofliver metastases. Acta Radiol 22: 15–23Google Scholar
  289. 68.
    Varna J, Huben RP, Wajsman Z, Pontes JE (1984) Therapeutic embolization of pelvic metastases of renal cell carcinoma. J Urol 131: 647–649Google Scholar
  290. 69.
    Vogelsang H, Schmidt RC (1980) Therapeutische Embolisation von kraniofazialen und spinalen Gefäßfehlbildungen sowie von Gefäßtumoren. Dtsch Aerztebl 14: 881–886Google Scholar
  291. 70.
    Wallace S, Chuang VP, Swanson D, Bracken B, Hersh EM, Ayala A, Johnson D (1981) Embolization of renal carcinoma. Radiology 138: 563–570PubMedGoogle Scholar
  292. 71.
    Wallace S, Charnsangavej, Ch, Carrasco CH, Bechtel W (1984) Ethanol for hepatic artery embolization. Radiology 152: 821–822PubMedGoogle Scholar
  293. 72.
    Weber J, Kaufmann J, Kult K (1984) Palliative Nierentumorembolisation mittels Jodoel-markiertem Ethibloc. Fortschr Röntgenstr 141: 384–389Google Scholar
  294. 73.
    White RI, Kaufmann SL, Barth KH, DeCaprio V et al. (1979) Embolotherapy with detachable silicone balloons. Radiology 131: 619–627PubMedGoogle Scholar
  295. 74.
    Wilner HI, Lazo A, Metes JJ, Beil KA et al. (1987) Embolization in cataclysmal hemorrhage caused by squamous cell carcinomas of the head and neck. Radiology 163: 759–762PubMedGoogle Scholar
  296. 75.
    Yamada R, Sato M, Kawabata M, Kakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397–401PubMedGoogle Scholar
  297. 76.
    Zollikofer Ch, Castaneda-Zuniga WR, Galliani C, Rysavy JA et al. (1980) Therapeutic blockade of arteries using compressed ivalon. Radiology 136: 635–640PubMedGoogle Scholar
  298. 1.
    Aggarwal BB, Eessalu TE, Hass PE (1985) Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature 318: 665PubMedGoogle Scholar
  299. 2.
    Agnantis NJ, Spandidos DA (1988) Immunohistochemical analysis of ras and c-myc oncoproteins in human lesions of breast, uterus and colon. Abstracts of the Second International Conference of Anticancer Research, Saronis/Greece, Abstr No 270, p 1102Google Scholar
  300. 3.
    Balkwill FR, Smyth JF (1987) Interferons in cancer therapy: a reappraisal. Lancet II: 317Google Scholar
  301. 4.
    Balkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor St, Durbin H, Fiers W (1987) Evidence for tumour necrosis factor/ cachectin production in cancer. Lancet II: 1229Google Scholar
  302. 5.
    Beaupain R, Billard C, Falcoff E (1986) Effects of human recombinant interferons-α2, -β and-γ on growth and survival of human cancer nodules maintained in continuous organotypic culture. Eur J Cancer Clin Oncol 22: 141PubMedGoogle Scholar
  303. 6.
    Berd D, Mastrangelo MJ (1987) Elimination of immune suppressor mechanisms in humans by oxazaphosphorines. Methods Find Exp Clin Pharmacol 9: 569PubMedGoogle Scholar
  304. 7.
    Boraschi D, Tagliabue A (1984) Multiple modulation of macrophage functions by lymphokines: different effects of interferon and macrophage activating factor. Lymphokines 9: 71Google Scholar
  305. 8.
    Boraschi D, Soldateschi D, Tagliabue A (1982) Macrophage activation by interferon: dissociation between tumorcidal capacity and supressive activity. Eur J Immunol 12: 320PubMedGoogle Scholar
  306. 9.
    Boraschi D, Censini S, Bartalini M, Scapigliati G, Barbarulli G, Vicenzi E, Donati MB, Tagliabue A (1984) Interferon inhibits prostaglandin biosynthesis in macrophages: effects on arachidonic acid metabolism. J Immunol 132: 1987PubMedGoogle Scholar
  307. 10.
    Boraschi D, Censini S, Tagliabue A (1984) Interferon-γ reduces macrophage suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. J Immunol 133: 764PubMedGoogle Scholar
  308. 11.
    Boraschi D, Censini S, Bartalani M, Tagliabue A (1985) Regulation of arachidonic acid metabolism in macrophages by immune and nonimmune interferons. J Immunol 135–502Google Scholar
  309. 12.
    Buckle AM, Potter CW, Rees RC, Rogers K, Jacob G (1988) HLA antigen expression in colon carcinoma cells. Abstracts of the Second International Conference of Anticancer Research, Saronis/Greece, Abstr No 269, p 1102Google Scholar
  310. 13.
    Burger CJ, Elgert KD, Farrar WL (1984) Interleukin 2 (IL-2) activity during tumor growth: IL-2 production, kinetics, absorption of and responses to exogenous IL-2. Cell Immunol 84: 228PubMedGoogle Scholar
  311. 14.
    Cianciolo G, Hunter J, Silva J, Haskill JS, Snyderman R (1981) Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15 (E) structural protein of retroviruses. J Clin Invest 68: 831PubMedGoogle Scholar
  312. 15.
    Clercq E de, Zhang ZX, Huygen K (1982) Synergism in the antitumor effects of type I and type II interferon in mice inoculated with leukemia L1210 cells. Cancer Lett 15: 223PubMedGoogle Scholar
  313. 16.
    Cochran AJ, Wen DR, Fanad Z, Stene MA, Lana AMA, Hoon DSB, Morton DL (1988) Immune suppression by melanoma cells as a factor in the generation of metastatic disease. Abstracts of the Second International Conference of Anticancer Research, Saronis/Greece, Abstr No 369, p 1130Google Scholar
  314. 17.
    Cunningham-Rundles S, Filippa DA, Braun OW Jr, Antonelli P, Ashikari H (1981) Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer in women. JNCI 67: 585PubMedGoogle Scholar
  315. 18.
    Czarniecki CW, Fennie CW, Powers DB, Estell DA (1984) Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. J Virol 49: 490PubMedGoogle Scholar
  316. 19.
    Davies P, Bonney RJ, Humes JL, Kuehl FA jr (1980) The synthesis of arachidonic acid oxygenation products by various mononuclear phagocyte populations. In: Furth R van (ed) Mononuclear phagocytes. Functional aspects. Nijhoff, The Hague, p 1317Google Scholar
  317. 20.
    Dean RT, Virelizier JL (1983) Interferon as a macrophage activating factor. I Enhancement of cytotoxicity by fresh and matured human monocytes in the absence of other soluble signals. Clin Exp Immunol 51: 501PubMedGoogle Scholar
  318. 21.
    Deodhar SC, Crile G, Esselstyn CB jr (1972) Study of the tumor cell-lymphocyte interaction in patients with breast cancer. Cancer 29: 132Google Scholar
  319. 22.
    Didier M (1987) Abstrakt auf dem gemeinsamen Kongreß der Schweizerischen und Französischen Gesellschaften für Allerlogie und Immunologie in GenfGoogle Scholar
  320. 23.
    Drews J (1986) Immunpharmakologie und Perspektiven. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  321. 24.
    Droller MJ, Perlmann P, Schneider MU (1978) Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell Immunol 39: 154PubMedGoogle Scholar
  322. 25.
    Edwards BS, Hawkins MJ, Borden EC (1984) Comparative in vivo and in vitro activation of human natural killer cells by two recombinant α-interferons differing in antiviral activity. Cancer Res 44: 3135PubMedGoogle Scholar
  323. 26.
    Ehrke MJ, Mihich E (1985) Effects of anticancer agents on immune responses. Trends Pharmacol Sci October: 412Google Scholar
  324. 27.
    Fleischmann WR Jr (1982) Potentiation of the direct anti cellular activity of mouse interferons: mutual synergism and interferon concentration dependence. Cancer Res 42: 869PubMedGoogle Scholar
  325. 28.
    Gershon RK (1975) A disquisition on Suppressor T cells. Transplant Rev 26: 170PubMedGoogle Scholar
  326. 29.
    Gewant WC, Chasin L, Tilson MD (1972) Lymph node-breast carcinoma interrelations in tissue culture. Surg Gynecol Obstet 133: 959Google Scholar
  327. 30.
    Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727PubMedGoogle Scholar
  328. 31.
    Goodwin JS (1981) Prostaglandin E and cancer growth: potential for immunotherapy with prostaglandin synthetase inhibitors. In: Hersh EM et al. (eds), Augmenting agents in cancer therapy. Raven, New York, p 393Google Scholar
  329. 32.
    Hansen K, Mossman BT (1987) Generation of superoxide (O2) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 47: 1681PubMedGoogle Scholar
  330. 33.
    Heberman RB, Ortaldo JR, Bonnard GO (1979) Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 227: 221Google Scholar
  331. 34.
    Heberman RB, Ortaldo JR, Mantovani A, Hobbs OS, Kung H-F, Pestka S (1982) Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 67: 160Google Scholar
  332. 35.
    Heideman E, Reichmann K, Wilms K, Trenner J, Niethammer O (1982) Effect of human fibroblast interferon on natural killer cell activity: stimulation in vitro and inhibition in vivo. Klin Wochenschr 60: 625Google Scholar
  333. 36.
    Hellström KE, Hellström J (1974) Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 18: 209PubMedGoogle Scholar
  334. 37.
    Hercend T, Schmidt RE (1988) Characteristics and uses of natural killer cells. Immunol Today 9: 291PubMedGoogle Scholar
  335. 38.
    Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH (1983) Inhibition of interleukin 2 production by factors released from tumor cells. J Immunol 131: 2837PubMedGoogle Scholar
  336. 39.
    Hickock OF (1972) The progressive lymph node defect in cancer patients. Surg Forum 21: 114Google Scholar
  337. 40.
    Höffken K, Meredith IB, Robins RA, Baldwin RW, Davies CJ, Blarney RW (1977) Circulating immune complexes in patients with breast cancer. Br Med J 2: 218PubMedGoogle Scholar
  338. 41.
    Hoon DSB, Korn EL, Cochran AJ (1987) Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res 47: 1740PubMedGoogle Scholar
  339. 42.
    Hoon DSB, Bowker RJ, Cochran AJ (1987) Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 47: 1529PubMedGoogle Scholar
  340. 43.
    Kaye J, Janeway CA (1984) Induction of receptors for interleukin 2 requires T cell Ag: la receptor crosslin king and interleukin 1. Lymphokine Res 3: 175PubMedGoogle Scholar
  341. 44.
    Kelley VE, Fiers W, Strom TB (1984) Cloned human interferon- γ, but not interferon-β or , induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol 132: 240PubMedGoogle Scholar
  342. 45.
    Keong A, Rabson AR (1983) Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells. Cancer Immunol Immunother 15: 178PubMedGoogle Scholar
  343. 46.
    Keong A, Herman J, Rabson AR (1983) Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity. Cancer Immunol Immunother 15: 183PubMedGoogle Scholar
  344. 47.
    Klein HO (1989) Untersuchungen zur Immuntherapie des metastasierenden Hypernephroms und anderer solider Tumoren. In: Kreidler I, Hündgen M (Hrsg) Aktuelle Immunologie 6, Regionale Tumortherapie mit Interferonen. Zuckschwerdt, München, S 13–29Google Scholar
  345. 48.
    Klein HO, Kreysch HG, Coerper C, Voigt P, Ruff I (1987) Preclinical and early clinical trial with mafosfamide as immune modulator. Methods Find Exp Clin Pharmacol 9: 627–640PubMedGoogle Scholar
  346. 49.
    Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ (1986) Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant γ-Interferon. Cancer Res 46: 5401PubMedGoogle Scholar
  347. 50.
    Koff WC, Fogler WE, Gutterman J, Fidler JJ (1985) Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon. Cancer Immunol Immunother 19: 85PubMedGoogle Scholar
  348. 51.
    Lloyd RE, Blalock JE, Stanton GJ (1982) Cell-to-cell transfer of interferon-induced antiproliferative activity. Science 221: 953Google Scholar
  349. 52.
    Lotzova E (1985) Effector immune mechanisms in cancer. Nat Immun Cell Growth Regul 4: 293PubMedGoogle Scholar
  350. 53.
    Lucero MA, Magdelenat H, Fridman WH, Pouillart P, Billardon C, Billiau A, Cantell K, Falcoff E (1982) Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients. Eur J Cancer Clin Oncol 18: 243PubMedGoogle Scholar
  351. 54.
    Metcalf D (1985) Multi CSF-dependent colony formation by cells of a murine hemopoietic cell line: specificity and action ofmulti-CSF. Blood 65: 357PubMedGoogle Scholar
  352. 55.
    Monson JRT, Ramsden C, Guillou PJ (1986) Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg 73: 483PubMedGoogle Scholar
  353. 56.
    Morgan DA, Ruscetti FW, Gallo RC (1976) Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 193: 1007PubMedGoogle Scholar
  354. 57.
    Nakamura M, Manser T, Pearson GDN, Daley MJ, Gefter ML (1984) Effect of IFN-γ on the immune response in vivo and on gene expression in vitro. Nature 307: 381PubMedGoogle Scholar
  355. 58.
    Natali PG, Nicotra MR, Venturo I, Bigotti A, Giacomini P, Russo C (1988) Loss of expression of polymorphic determinants of HLA-A,B,C antigens in solid tumors. Abstracts of the Second International Conference of Anticancer Research, Saronis/Greece, Abstr N0417, p 1147Google Scholar
  356. 59.
    Nathan CF, Horowith CR, Harpe J de la, Vadhan-Raj S, Sherwins St, Oettgen HF, Krown SE (1985) Administration of recombinant interferon γ to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 82: 8686PubMedGoogle Scholar
  357. 60.
    Niemeyer U, Engel J, Scheffler G, Molge K, Sauerbier D, Weigert W (1984) Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivate of 4-hydroxy-cyclophosphamide. Invest New Drugs 2: 133PubMedGoogle Scholar
  358. 61.
    Oettgen HF, Old U, Boyse EA (1971) Human tumor immunology. Med Clin North Am 55: 761PubMedGoogle Scholar
  359. 62.
    Old L (1987) Polypeptide mediator network. Nature 326: 330PubMedGoogle Scholar
  360. 63.
    Oleszak E, Stewart WE (1985) Potentiation of the antiviral and anticellular activities of interferons by mixtures of HuIFN-γ and HuIFN-α or HuIFN-β. J Interferon Res 5: 361PubMedGoogle Scholar
  361. 64.
    Olsson L, Mathe G, Reizenstein P (1984) The biologic and immunologic response to tumors. In: Kuemmerle HP (ed) Clinical Chemotherapy, vol III: Antineoplastic chemotherapy. Thieme & Stratton, New York, p 308Google Scholar
  362. 65.
    Ortaldo JR, Timonen T, Mantovani A, Pestka S (1981) The effect of interferon on natural immunity. J Interferon Res 1: 241Google Scholar
  363. 66.
    Peri G, Polentarutti K, Sessa C, Mangioni C, Mantovani A (1981) Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin. Int J Cancer 28: 143PubMedGoogle Scholar
  364. 67.
    Pluznik DH, Cunningham RE, Noguchi PO (1984) Colony-stimulating factor (CSF) controls proliferation of CSF-dependent cells by acting during the Gl phase of the cell cycle. Proc Natl Acad Sci USA 81: 7451PubMedGoogle Scholar
  365. 68.
    Rees RC, Buckle AM, Gelsthorpe K, James V, Potter CW, Rogers K, Jacob G (1988) Loss of polymorphic A and B locus HLA antigens in colon carcinoma. Br J Cancer 57: 374PubMedGoogle Scholar
  366. 69.
    Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9: 58PubMedGoogle Scholar
  367. 70.
    Rosenberg SA, Lotz MT, Muul LM et al. (1985) Observations in the systemic administration of autologous Iymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 313: 1485PubMedGoogle Scholar
  368. 71.
    Roth JA, Grimm EA, Gupta RK, Ames RS (1982) Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. J Immunol 128: 1955PubMedGoogle Scholar
  369. 72.
    Ruggiero V, Tavernier J, Fiers W, Baglioni C (1986) Induction of the synthesis of tumor necrosis factor receptors by interferon-γ. Immunology 136: 2445Google Scholar
  370. 73.
    Saiki J, Dunegan MA, Fann AV, Koff EC (1986) Regulatory effects on macrophages of human recombinant interferons-α. J Interferon Res 6: 603PubMedGoogle Scholar
  371. 74.
    Sakita M, Kageyama N, Majima S (1985) Comparative studies between liposomes containing muramyl dipeptide and various immunomodulators on activation of mouse peritoneal macrophages and NK cells. Oncology 42: 259PubMedGoogle Scholar
  372. 75.
    Schiller JH, Groveman OS, Schmid SM, Willson JKV, Cummings KB, Borden EC (1986) Synergistic anti proliferative effects of human recombinant α 54- or β-interferon with γ-interferon on human cell lines of various histogenesis. Cancer Res 46: 483PubMedGoogle Scholar
  373. 76.
    Schiller JH, Storer B, Willson JKV, Borden EC (1987) Phase I trial of combinations of recomb inant interferons and in patients with advanced malignancy. Cancer Treat Rep 71 : 945PubMedGoogle Scholar
  374. 77.
    Schrier PI, van’t Veer L, Versteeg R, Peltenburg L, Ruiter OJ, Burgering B, Bos HL (1988) Activation of oncogenes in human melanoma: a message to the immune system? Abstracts of the Second International Conference of Anticancer Research, Abstr No 372, p 1131Google Scholar
  375. 78.
    Schwarz T (1988) Melanome hemmen Killerzellen durch eigene Zytokine. Vortrag auf dem Symposium „Immunodeficiency and Skin‟, InnsbruckGoogle Scholar
  376. 79.
    Sidman CL, Marshall JD, Shultz LD, Gray PW, Johnson HM (1984) γ-interferon is one of several direct B cell-maturing Iymphokines. Nature 309: 801PubMedGoogle Scholar
  377. 80.
    Smith JJ, Mihich E, Ozer H (1987) In vitro effects of 4-hydroxyperoxy-cyclophosphamide on human immunoregulatory T subset function. Methods Find Exp Clin Pharmacol 9: 555PubMedGoogle Scholar
  378. 81.
    Szuro-Sudol A, Nathan CF (1982) Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med 156: 945PubMedGoogle Scholar
  379. 82.
    Thomas Y, Huchet R, Grandjon O (1981) Role of adherent suppressor cells in the depression of cell-mediated immunity in Hodgkin’s disease and lung carcinoma. Ann Inst Pasteur Immunol 132C: 167Google Scholar
  380. 83.
    Tilden AB, Balch CM (1982) A comparison of PGE2 effects on human suppressor cell function and on interleukin 2 function. J Immunol 129: 2469PubMedGoogle Scholar
  381. 84.
    Tsujimoto M, Yip YK, Vilcek J (1986) Interferon-γ enhances expression of cellular receptors for tumor necrosis factor. J Immunol 136: 2441PubMedGoogle Scholar
  382. 85.
    Vánky F, Stjernswärd J, Nilsonne U (1973) Differences in the tumor-associated reactivity of blood lymphocytes and tumor-draining lymph node cells in sarcoma patients. J NatI Cancer Inst 51: 17Google Scholar
  383. 86.
    Vose BM, Moore M (1985) Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 22: 27PubMedGoogle Scholar
  384. 87.
    Wasielewski E von, Sedlacek HH (1986) Alte und neue Probleme der Tumorforschung. Dtsch Med Wochenschr 111 : 630Google Scholar
  385. 88.
    Weigent DA, Langford MP, Fleischmann WR Jr, Stanton GJ (1983) Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon. Infect Immun 40: 35PubMedGoogle Scholar
  386. 89.
    Werkmeister J, McCarthy W, Hersey P (1981) Suppressor cell activity in melanoma patients. I. Relation to tumor growth and immunoglobulin levels in vivo. Int J Cancer 28: 1PubMedGoogle Scholar
  387. 90.
    Yip YK, Barrowclough BS, Urban C, Vi1cek J (1982) Molecular weight of human gamma interferon is similar to that of other human gamma interferons. Science 215: 411PubMedGoogle Scholar
  388. 91.
    Yu A, Watts H, Jaffe N, Parkman R (1977) Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. New Engl J Med 297: 121PubMedGoogle Scholar
  389. 92.
    Zembala M, Mytar B, Popiela T, Asherson GL (1977) Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells. Int J Cancer 19: 605PubMedGoogle Scholar
  390. 1.
    Ardenne M von (1987) Sauerstoff-Mehrschritt-Therapie, 4. Aufl. Thieme, StuttgartGoogle Scholar
  391. 2.
    Berger M, Schmähl D (1983) Studies on the tumor-inhibiting effects of Iscador in experimental animal tumors. J Cancer Res Clin Oncol 105: 262–265PubMedGoogle Scholar
  392. 3.
    Blumenschein W (1986) Biologische Heilweisen bei Krebs. Ennsthaler, SteyrGoogle Scholar
  393. 4.
    Bohn B, Nebe CT, Birr C (1987) Durchflußzytometrische Untersuchungen auf immunmodulatische Wirkungen von Eleutherococcus S.-Extrakt. Arzneimittelforschung 37: 1193–1196PubMedGoogle Scholar
  394. 5.
    Braun H, Frohne D (1987) Heilpflanzenlexikon fUr Arzte und Apotheker, 5. Aufl. Fischer, Stuttgart New YorkGoogle Scholar
  395. 6.
    Bruntsch U (1982) Entwicklung und Erprobung neuer Medikamente in der Onkologie. MMW 124: 356Google Scholar
  396. 7.
    Curtze A (o Jg) Ein Pflanzenextrakt im Einsatz gegen Krebs (Firmenbroschüre Neu-Isenburg)Google Scholar
  397. 8.
    Diet, Nutrition and Cancer (1982) National Academy Press, Washington DC [deutsch: Ernährung und Krebs (1984) BMFT Bonn]Google Scholar
  398. 9.
    Dold U (1986) Neue und alternative Therapieformen des Bronchialkarzinoms. 32. Kongrs. Dtsch Ges Pneumol TuberkuloseGoogle Scholar
  399. 10.
    Fasching (1988) Teepilz Kombucha, 9. erw Aufl. Ennsthaler, SteyrGoogle Scholar
  400. 11.
    Gutsch J (1988) Prospektive Studie beim radikal operierten Mamma-Karzinom mit Polychemotherapie, Helixor und unbehandelter Kontrolle. Dtsch Onkol 20: 94Google Scholar
  401. 12.
    Hauser SP (1987) Krebspatient und Paramedizin. Praxis 76: 1151–1178 (Sondernummer 42)Google Scholar
  402. 13.
    Hornung J (1989) Methodisches zu den klinischen Studien zur Misteltherapie des Krebses. Therapeutikon 3: 16–21Google Scholar
  403. 14.
    Jäger G (1988) Leben mit Krebs. Mosaik, MünchenGoogle Scholar
  404. 15.
    Jungi WF (1985) Moglichkeiten und Grenzen alternativer Krebstherapie. Kassenarzt 31: 17Google Scholar
  405. 16.
    Jungi WF (1986) Risiken alternativer Krebsbehandlung. Onkologie 9: 231PubMedGoogle Scholar
  406. 17.
    Jungi WF (1988) Alternativen zur Schulmedizin in der Krebstherapie. Krankenhausarzt 61: 145–150Google Scholar
  407. 18.
    Jungi WF (1988) Diätetik bei Krebserkrankungen. Internist 29: 492–498PubMedGoogle Scholar
  408. 19.
    Jungi WF, Senn HJ (Hrsg) (1986) Krebs und Alternativmedizin. Zuckschwerdt, München Bern Wien San FranciscoGoogle Scholar
  409. 20.
    Kjaer M (1988) Misteltenbehandling af metastaserende nyrecancer. Ugeskr Laeger 150: 1923PubMedGoogle Scholar
  410. 21.
    Leroi R (1987) Misteltherapie. Freies Geistesleben, StuttgartGoogle Scholar
  411. 22.
    Luther P, Becker H (1987) Die Mistel. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  412. 23.
    Nagel GA, Schmahl D, Hossfeld DK (1989) Krebsmedikamente mit fraglicher Wirksamkeit, 4. Aufl. Aktuelle Onkologie 49, Zuckschwerdt, München Bern Wien San FranciscoGoogle Scholar
  413. 24.
    Oepen I (Hrsg) (1985) An den Grenzen der Schulmedizin. Deutscher Ärzteverlag, KölnGoogle Scholar
  414. 25.
    Renner H (1979) Klinische Aspekte einer Tumorimmuntherapie mit lyophilisierten fetalen Zellen. Cytobiol Rev 3: 3–6Google Scholar
  415. 26.
    Renner H et al. (1980) Erfahrungen mit Resistocell als Zusatztherapie beim metastasierenden Mammacarcinom. Cytobiol Rev 4: 109–114Google Scholar
  416. 27.
    Salzer G (1988) Prospektiv randomisierte Studie: Operiertes Magenkarzinom. Dtsch Z Onkol 20: 90–93Google Scholar
  417. 28.
    Salzer G, Havelec L (1983) Adjuvante Iscadorbehandlung nach operiertem Magenkarzinom. Krebsgeschehen 15: 106Google Scholar
  418. 29.
    Schmähl D, Berger M (1983) Gedanken zur sogenannten unkonventionellen Krebsbehandlung. Med Welt 34: 3Google Scholar
  419. 30.
    Schmähl D, Einem J von (1956) Experimentelle Prüfung von „Krebsmitteln‟. Dtsch Med Wochenschr 81: 293PubMedGoogle Scholar
  420. 31.
    Schnizer W et al. (1985) Untersuchungen zur Krebs-Mehrschritt-Therapie nach von Ardenne. Dtsch Ärztebl 82: 2026–2028Google Scholar
  421. 32.
    Schreml W (1984) Zytoplasmatische Therapie. MMW 126: 234–238Google Scholar
  422. 33.
    Schumacher K (1986) Die Problematik der sogenannten unkonventionellen Krebstherapie. Med Klin 81: 423Google Scholar
  423. 34.
    Schweiz Krebsliga/Schweiz Ges Onkol (1989) Dokumentationen der Studiengruppe mit unbewiesener Wirkung in der Onkologie, Nr.I-22 (Sammelseparatum aus Schweiz Rundsch Med Prax)Google Scholar
  424. 35.
    Theurer KE (Hrsg) (1985) Neue Perspektiven in der Onkologie. Therapiewoche 35: 77–130Google Scholar
  425. 36.
    Wobe-Mugos (1987) Broschüre. Fa. Mucos, Geretsried/WienGoogle Scholar
  426. 1.
    Anemueller H (1980) Das Grunddiät-System. Leitfaden der Emährungstherapie. Hippokrates, StuttgartGoogle Scholar
  427. 2.
    Armstrong BK, McMichael AJ, MacLennan R (1982) Diet. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention. Saunders, PhiladelphiaGoogle Scholar
  428. 3.
    Brenner U (1987) Emahrungsstörungen durch chirurgische Eingriffe. In: Sauer R, Thiel H-J (Hrsg) Emährungsprobleme in der Onkologie. Zuckschwerdt, MünchenGoogle Scholar
  429. 4.
    Canzler H (1983) Die Emährung des Krebskranken. In: Schlierf G (Hrsg) Emährung und Krebs. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  430. 5.
    Committee on Diet, Nutrition, and Cancer - National Research Council (1982) Diet, nutrition, and cancer. National Academy Press, Washington DC. [Deutsche Übersetzung der Zusammenfassung: Ernährung und Krebs (1984) Bundesministerium f. Forschung u. Technologie, Bonn]Google Scholar
  431. 6.
    Douwes FR (1984) Ernährungstherapie bei Krebskranken. Ärztez Naturheilverf 25: 5Google Scholar
  432. 7.
    Jungi WF (1982) Was von „Krebsdiaten‟ zu halten ist. MMW 124: 26Google Scholar
  433. 8.
    Koerber KW von, Männie T, Leitzmann C (1982) Vollwert-Ernährung, 2.Aufl Haug, HeidelbergGoogle Scholar
  434. 9.
    Kollath W (1951) Die Ordnung unserer Nahrung, 2. Aufl. Hippokrates, StuttgartGoogle Scholar
  435. 10.
    Lützner H (1983) Aktive Diätetik bei chronischen Leberkrankheiten. Ärztez Naturheilverf 24: 518Google Scholar
  436. 11.
    Müller JM, Brenner U, Schindler J (1982) Das Kurzdarrn-Syndrom. Leber Magen Darrn 12: 60Google Scholar
  437. 12.
    Ollenschläger G, Jansen S, Fischer H, Mödder B (1987) Zur Pathogenese und klinischen Bedeutung der Anorexie onkologischer Patienten. In: Sauer R, Thiel H-J (Hrsg) Ernährungsprobleme in der Onkologie. Zuckschwerdt, MünchenGoogle Scholar
  438. 13.
    Pischinger A (1980) Das System der Grundregulation, 3. Aufl. Haug, HeidelbergGoogle Scholar
  439. 14.
    Rauch E (1988) Blut- und Säfte-Reinigung, 18.Aufl. Haug, HeidelbergGoogle Scholar
  440. 15.
    Strohmeyer G (1988) Diätetik und künstliche Ernährung. In: Riecker G (Hrsg) Therapie innerer Krankheiten, 6. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  441. 16.
    Theologides A (1979) Cancer cachexia. Cancer 43: 2004PubMedGoogle Scholar
  442. 17.
    Thiel H-J (1987) Ernahrungsstorungen durch Strahlentherapie. Ursachen-Prophylaxe-Therapie. In: Sauer R, Thiel H-J (Hrsg) Ernährungspröbleme in der Onkologie. Zuckschwerdt, MünchenGoogle Scholar
  443. 18.
    Thielemann-Jonen I (1982) Probleme nach chirurgischen Eingriffen am Dickdarrn. Leber Magen Darrn 12: 64Google Scholar
  444. 19.
    Zabel W (1980) Die interne Krebstherapie und die Ernährung des Krebskranken, 8.Aufl. Bircher-Benner, Bad Homburg v. d. H. ZürichGoogle Scholar
  445. 1.
    Bothe A jr, Valerio D, Bistrian BR, Blackburn GL (1979) Randomized control trial of hospital nutritional support during abdominal radiotherapy. J Parenter Enter Nutr 3: 292Google Scholar
  446. 2.
    Brennan MF (1981) Total parenteral nutrition of the cancer patient. N EnglJ Med 305: 375Google Scholar
  447. 3.
    Broviac JW, Cole JJ, Scribner BH (1973) A silicone rubber atrial catheter for prolonged parenteral nutrition. Surg Gynecol Obstet 136: 602PubMedGoogle Scholar
  448. 4.
    Flemming CR, Witzke DJ, Beart R W (1980) Catheter-related complications in patients receiving home parenteral nutrition. Ann Surg 192: 593Google Scholar
  449. 5.
    Food and Nutrition Board (1973) Recommended dietary allowances, 8th rev edn. National Academy of Science, Washington D. C.Google Scholar
  450. 6.
    Issell BF, Valdivieso M, Zaren HA (1978) Protection against chemotherapy toxicity by IV hyperalimentation. Cancer Treat Rep 62: 1139PubMedGoogle Scholar
  451. 7.
    Miller DG, Ivey M, Ivey T, Scribner BH (1980) Experience with an indwelling right atrial catheter for home parenteral nutrition. Surg Gynecol Obstet 151: 108PubMedGoogle Scholar
  452. 8.
    Müller JM (1982) Die parenterale Ernährung zu Hause. Travenol, München (Ein Handbuch für Patienten)Google Scholar
  453. 9.
    Müller JM, Keller HW, Brenner U, Walter M (1984) Stoffwechselkonsequenzen der parenteralen Ernährung bei Tumorpatienten. Leber Magen Darm 14: 68PubMedGoogle Scholar
  454. 10.
    Müller JW, Keller HW, Brenner U, Walter M (1984) Die ambulante parenterale Dauerernahrung bei Kranken mit Kurzdarmsyndrom. Internist 25: 292PubMedGoogle Scholar
  455. 11.
    Nixon D, Rudman D, Heymsfield S (1979) Abnormal hyperalimentation response in cachectic cancer patients. Proc Am Assoc Cancer Res Am Soc Clin Oncol 20: 173Google Scholar
  456. 12.
    Shamberger RC, Brennan MF, Goodgame JT (1981) Effect of total parenteral nutrition (TPN) on metabolic parameters of patients undergoing ablative chemotherapy. Proc Am Assoc Cancer Res Am Soc Clin Oncol 22: 420Google Scholar
  457. 13.
    Steiger E, Grundfest S (1979) Experience with the BROVIAC-catheter for prolonged parenteral alimentation. J Parenter Enter Nutr 3: 45Google Scholar
  458. 14.
    Strobel CT, Byrne WJ, Ament ME (1979) Home parenteral nutrition in children with Crohn’s disease. An effective management alternative. Gastroenterology 77: 272PubMedGoogle Scholar
  459. 15.
    Valerio D, Overett L, Malcolm A, Blackburn GL (1978) Nutritional support for cancer patients receiving abdominal and pelvic radiotherapy: a randomized prospective clinical experiment of intravenous versus oral feeding. Surg Forum 29: 145PubMedGoogle Scholar
  460. 1.
    Baines M (1983) The principles of symptom control. In: Saunders C, Summers DH, Teller N (eds) Hospice: the living idea, 2nd edn. Arnold, LondonGoogle Scholar
  461. 2.
    Baines M (1984) Control of other symptoms. In: Saunders C (ed) The management of terminal malignant disease, 2nd edn. Arnold, LondonGoogle Scholar
  462. 3.
    Regnard CFB, Davies A (1986) A guide to symptom relief in advanced cancer, 2nd edn Haigh & Hochland, ManchesterGoogle Scholar
  463. 4.
    Saunders C, Baines M (1984) Living with dying. The management of terminal disease, 3rd edn. Oxford University Press, OxfordGoogle Scholar
  464. 5.
    Stott NCH, Finlay IG (1986) Care of the dying, 2nd edn. Churchill Livingstone, EdinburghGoogle Scholar
  465. 6.
    Twycross RG, Lack SA(1984) Symptom control in far advanced cancer: Pain relief, 2nd edn. Pitman, LondonGoogle Scholar
  466. 7.
    Twycross RG, Lack SA (1986) Control of alimentary symptoms in far advanced cancer. Churchill Livingstone, EdinburghGoogle Scholar
  467. 8.
    Twycross RG, Lack SA (1986) Therapeutics in terminal cancer, 2nd edn. Churchill Livingstone, EdinburghGoogle Scholar
  468. 9.
    Twycross RG, Lack SA (1989) Therapie bei Krebs im Endstadium. Fischer, Stuttgart New York (Übersetzung und Bearbeitung von Göpfert C)Google Scholar
  469. 1.
    Aaronson NK, Beckmann I (1987) Quality of life of cancer patients. Raven, New YorkGoogle Scholar
  470. 2.
    Aaronson NK, Bullinger M, Ahmedzai S (1988) A modular approach to quality of life. In: Scheurlen H (ed) Recent results in cancer research: Cancer clinical trials. Heidelberger Symposium 3.87, Freiburg (Breisgau), Vol 111. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  471. 3.
    Ackenheil M (1985) Spektrum Psychopharmaka. Aesopus, Zug (Arzneimitteltherapie heute, Band 36)Google Scholar
  472. 4.
    Adami S, Salvagno G, Guarrera G et al. (1985) Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Uroll 34: 1152–1154Google Scholar
  473. 5.
    Adler RH, Hürny C (1988) Differential diagnosis of pain in cancer patients. Rec Res Cancer Res 108: 1–8Google Scholar
  474. 6.
    Ahles TA, Blanchard EB, Ruckdeschel JC (1983) The multi-dimensional nature of cancer-related pain. Pain 17: 277–288PubMedGoogle Scholar
  475. 7.
    Ahuja BR (1983) Analgesic effect of intrathecal ketamine in rats. Br J Anaesth 55: 991–995PubMedGoogle Scholar
  476. 8.
    Aly A (1987) Prostaglandins in clinical treatment of gastroduodenal mucosal lesions : A review. Scand J Gastroenterol [Suppl] 22/134: 43–49Google Scholar
  477. 9.
    Ameer B, Greenblatt OJ (1977) Acetaminophen. Ann Intern Med 87: 202PubMedGoogle Scholar
  478. 10.
    American Pain Society (1987) Principles of analgesic use in the treatment of acute pain or chronic cancer pain. Clin Pharmacology 6: 523–532Google Scholar
  479. 11.
    Armstrong PJ, Bersten A (1986) Normeperidine toxicity. Anesth Analg 65: 536–538PubMedGoogle Scholar
  480. 12.
    Arnér S, Arnér B (1984) Effects of epidural morphine on different types of pain associated with cancer. Pain [Suppl] 2: S 18Google Scholar
  481. 13.
    Baines MJ (1984) Cancer pain. Postgrad Med J 60: 852–857PubMedGoogle Scholar
  482. 14.
    Baines MJ (1988) Nausea and vomiting in the patients with advanced cancer. J Pain Sympt Manag 312: 81–85Google Scholar
  483. 15.
    Barkas G, Duafala ME (1988) Advances in cancer pain management: A review of patient-controlled analgesia. J Pain Sympt Manag 3: 150–160Google Scholar
  484. 16.
    Beaver WT, Wallenstein SL, Houde RW, Rogers A (1966) A comparison of the analgesic effects of methotrimeprazine and morphine in patients with cancer. Clin Pharmacol Ther 5: 436–446Google Scholar
  485. 17.
    Bennett RL (1985) Patient-controlled analgesia for the treatment of the pain of terminal cancer. In: Harmer M, Rosen M, Vickers MD (eds) Patient-controlled analgesia. Blackwell, OxfordGoogle Scholar
  486. 18.
    Bernatzky G, Jurna I (1986) Intrathecal injection of codein, buprenorphine, tilidine, tramadol, nefopam depresses the tail-flick responds in rats. Eur J Pharmacol 120: 75–80PubMedGoogle Scholar
  487. 19.
    Bischko J (1978) Verwendung des Laserstrahls in der Akupunktur. MMW 120 (2–3): 67–68Google Scholar
  488. 20.
    Blanchard J, Menk EJ, Ramamurthy S, Hoffman J (1988) Subarachnoid and epidural calcitonin for the management of cancer pain. Anesth Analg 67 :S17Google Scholar
  489. 21.
    Bonica JJ (1978) Cancer pain: a major national health problem. Cancer Nurs 1: 313–316PubMedGoogle Scholar
  490. 22.
    Bonica JJ (1985) Control of bone cancer pain. In: Garattini S (ed) Bone resorption, metastasis, and diphosphonates. Raven, New York, pp 137–180Google Scholar
  491. 23.
    Bonica JJ, Halpern LM (1972) Analgesics. In: Drugs of choice 1972–73. Mosby, St. Louis, pp 185–217Google Scholar
  492. 24.
    Boreus LO, Sandberg F (1959) The influence of three phenothiazine derivates and of amiphenazole on the action of methadone. J Pharmacol 11: 449–455Google Scholar
  493. 25.
    Bowdler I (1989) Die rückenmarknahe Applikation von analgetisch wirkenden Substanzen. In: Hankemeier U, Bowdler I, Zech D (Hrsg) Tumorschmerztherapie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  494. 26.
    Breukelen FJM, van Bijvoet OLM, Osterom AT (1979) Inhibition of osteolytic bone lesions by (3-amino-1-hydroxy-propylidene)-1,1 biphosphonate (ADP). Lancet 14: 803–805Google Scholar
  495. 27.
    Brigden ML, Barnett JM (1987) A practical approach to improving pain control in cancer patients. West J Med 146: 580–584PubMedGoogle Scholar
  496. 28.
    Bromm B, Meier W, Scharein E (1983) Antagonism between tilidine and naloxone on cerebral potentials and pain rating in man. Eur J Clin Pharmacol 87: 431–439Google Scholar
  497. 29.
    Bromm B, Herrmann MW, Scharein E (1988) Zur analgetischen Wirksamkeit von Paracetamol und Acetylsalicylsiiure im experimentellen Schmerzmodell. Schmerz Pain Douleur 9: 5–11Google Scholar
  498. 30.
    Bruera E, Roca E, Cedaro L et al. (1985) Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 69: 751–754PubMedGoogle Scholar
  499. 31.
    Bruera E, Brennels C, Michaud M et al. (1987) Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer. Cancer Treat Rep 71/6: 635–637PubMedGoogle Scholar
  500. 32.
    Brune K (1984) Peripher wirkende Analgetika. In: Zimmermann M, Handwerker O (Hrsg) Schmerz - Konzepte und ärztliches Handeln. Springer, Berlin Heidelberg New York Tokyo, S44–60Google Scholar
  501. 33.
    Brune K (1986) Comparative pharmacology of „non-opioid‟ analgesics. Med Toxicol 1 [Suppl 1]: 1–9PubMedGoogle Scholar
  502. 34.
    Brune K (1986) Pharmakologie der peripher wirkenden Analgetika. In: Mihatsch MJ (Hrsg) Das Analgetikasyndrom. Thieme, Stuttgart, S 3–18Google Scholar
  503. 35.
    Brune K (1986) Schmerzmittel auf dem Prüfstand. Fortschr Med 104/25: 483–488PubMedGoogle Scholar
  504. 36.
    Brune K, Lanz R (1984) Mode of action of peripheral analgesics. Arzneimittelforschung 34 (II)/9a: 1060–1065PubMedGoogle Scholar
  505. 37.
    Brune K, Dietzel K, Möller N (1986) Pharmakologie des Schmerzes. In: Wörz R (Hrsg) Pharmakotherapie bei Schmerz. VHC, Weinheim, S 45–93Google Scholar
  506. 38.
    Buy IN, Moss AA., Singler RC (1982) CT guided celiac plexus and splanchnic nerve neurolysis. J Comput Assist Tomogr 6/2: 315–319PubMedGoogle Scholar
  507. 39.
    Campbell CF, Mason JB, Weiler JM (1983) Continuous subcutaneous infusion of morphine for the pain of terminal malignancy. Ann Intern Med 98/1: 51–52PubMedGoogle Scholar
  508. 40.
    Carlsson KH, Helmreich J, Jurna I (1986) Activation of inhibition from the periaqueductal grey matter mediates central analgesic effect of metamizol (dipyrone). Pain 27: 373–390PubMedGoogle Scholar
  509. 41.
    Carlsson KH, Helmreich J, Jurna I (1986) Comparison of central antinociceptive and analgesic effects of the pyrazolone derivates, metamizol (Dipyrone) and aminophenazone („Pyramidon‟). Schmerz Pain Douleur 3: 93–100Google Scholar
  510. 42.
    Casey KL (1982) Neural mechanisms of pain: An overview. Acta Anaesthesiol Scand [Suppl] 74: 13Google Scholar
  511. 43.
    Cavenar JO, Maltebie AA (1976) Another indication for haloperidol. Psychosomatics 17: 128–130PubMedGoogle Scholar
  512. 44.
    Challenger JH (1978) Sympathetic nervous system blocking and pain relief. In: Swerdlow M (ed) Relief of intractable pain, 2nd edn. Elsevier, Amsterdam, pp 157–182Google Scholar
  513. 45.
    Chatterton P (1988) Physiotherapy for the terminally ill. Physiotherapy 74/1: 42–46Google Scholar
  514. 46.
    Chrubasik J, Falke KJ, Blond S, Meynadier J (1987) Epidural salmon calcitonin-infusion in treatment of cancer pain. Schmerz Pain Douleur 1: 23–27Google Scholar
  515. 47.
    Cleeland CS (1987) Nonpharmacological management of cancer pain. J Pain Sympt Manag 2/2: S23–S28Google Scholar
  516. 48.
    Cooper SA (1981) Comparative efficacies of aspirin and acetaminophen. Arch Intern Med 141: 23Google Scholar
  517. 49.
    Copping J, Willix R, Kraft R, Arbor A (1969) Palliative chemical splanchnicectomy. Arch Surg 98: 418–420PubMedGoogle Scholar
  518. 50.
    Cordes M, Panitz N, Utech C (1987) Schmerztherapie bei Knochenmetastasen. Dtsch Med Wochenschr 112/10: 405PubMedGoogle Scholar
  519. 51.
    Cowie RA, Hitchcock ER (1982) The late results of anterolateral cordotomy for pain relief. Acta Neurochir 64: 39–50Google Scholar
  520. 52.
    Coyle N, Mauskop A, Maggard J, Foley K (1986) Continuous subcutaneous infusions of opiates in cancer patients with pain. Oncol Nurs Forum 13/4: 53–57PubMedGoogle Scholar
  521. 53.
    Daftary SN, Mehta AC, Nunavati N (1980) A controlled comparison of dipyrone and paracetamol in postoperative pain. Curr Med Res Opin 6: 614PubMedGoogle Scholar
  522. 54.
    Dammann HG, Dau B, Dreyer M, Walter THA, Müller P, Simon B (1987) Endoskopische Untersuchungen zur Magenverträglichkeit von Acetylsalicylsäure (ASS) und anderen nichtsteroidalen Antirheumatika beim Menschen - ein Überblick. In: Simon B (Hrsg) Nichtsteroidale Antirheumatika und Gastrointestinaltrakt. Schattauer, Stuttgart, S 49–69Google Scholar
  523. 55.
    Daut RL, Cleeland CS (1982) The prevalence and severity of pain in cancer. Cancer 50: 1914–1918Google Scholar
  524. 56.
    Desmeules J, Dayer P (1988) Why is codeine unreliable for cancer pain control? J Pain Sympt Manag 3/3: S20Google Scholar
  525. 57.
    Devor M, Govrin-Lippmann R, Raber P (1985) Corticosteroids suppress ectopic neural discharge originating in experimental neuromas. Pain 22: 127–137PubMedGoogle Scholar
  526. 58.
    Dickson RJ, Russell PSB (1982) Continuous subcutaneous analgesics for terminal care at home. Lancet I: 165Google Scholar
  527. 59.
    Dickson RJ, Howard B, Campbell J (1984) The relief of pain by subcutaneous infusion of diamorphine. In: Wilkes E (ed) Advances in morphine therapy. Royal Society of Medicine International Congress and Symposiums Series, No. 64, LondonGoogle Scholar
  528. 60.
    Dorn M (1987) Ibuprofen in der klinischen Praxis. Rheuma + Schmerz u. Entzündung 7/1: 29–36Google Scholar
  529. 61.
    Droste C (1986) Medikamentöse Schmerztherapie in der Inneren Medizin. In: Wörz R (Hrsg) Pharmakotherapie bei Schmerz. VHC, Weinheim, S 95–190Google Scholar
  530. 62.
    Elliott F, Little A, Milbrandt W (1976) Carbamazepin for phantom-limb phenomena. N Engl J Med 295: 678PubMedGoogle Scholar
  531. 63.
    Elomaa I, Blomqvist C, Gröhn P et al. (1983) Long term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet I: 146–149Google Scholar
  532. 64.
    Ettinger AB, Portenoy RK (1988) The use of Corticosteroids in the treatment of symptoms associated with cancer. J Pain Sympt Manag 3/2: 99–103Google Scholar
  533. 65.
    Fahrliinder H (1986) Analgetika und Magen. In: Mihatsch MJ (Hrsg) Das Analgetikasyndrom. Thieme, Stuttgart, S 42–46Google Scholar
  534. 66.
    Farcot JM, Laugner B, Muller A, et al. (1983) Subdural-arachnoid neurolytic block in cervical pain. Pain 17: 316–317PubMedGoogle Scholar
  535. 67.
    Filshie J, Redman D (1985) Acupuncture and malignant pain problems. Eur J Clin Oncol 11: 389–394Google Scholar
  536. 68.
    Filshie J, Golding S, Robbie DS, Husband JE (1983) Unilateral computerized tomography guided coeliac plexus block: a technique for pain relief. Anaesthesia 38: 498–503PubMedGoogle Scholar
  537. 69.
    Fiore CE, Castorina F, Malatino LS, Tamburino C (1983) Analgesic activity of calcitonin: Effectiveness of the epidural and subarachnoidal routes in man. Int J Clin Pharmacol Res 3: 257PubMedGoogle Scholar
  538. 70.
    Fischer MV, Eibach J, Schmidt M (1986) Schmerztherapie beim Tumorpatienten. Anaesth Intensivther Notfallmed 21: 78–81Google Scholar
  539. 71.
    Flanigan DP, Kraft RO (1978) Continuing experience with palliative chemical splanchnicectomy. Arch Surg 113: 509–511PubMedGoogle Scholar
  540. 72.
    Flower FJ, Vane JR (1972) Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-Acetaminophenol). Nature 240: 410PubMedGoogle Scholar
  541. 73.
    Foley KM (1979) Pain syndromes in patients with cancer. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy, vol 2. Raven, New York, pp 59–75Google Scholar
  542. 74.
    Foley KM (1985) The treatment of cancer pain. N Engl J Med 313: 84–95PubMedGoogle Scholar
  543. 75.
    Foley KM (1987) Cancer pain syndromes. J Pain Sympt Manag 2: 13–17Google Scholar
  544. 76.
    Foley KM, Sundaresan N (1985) Management of cancer pain. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer - Principles and practice of oncology. Lippincott, Philadelphia, pp 1940–1961Google Scholar
  545. 77.
    Forth W (1985) Spasmolytische Effekte von Pyrazolonen. In: Brune K, Lanz R (Hrsg) 100 Jahre Pyrazolone. Urban & Schwarzenberg, München, S 139–143Google Scholar
  546. 78.
    Fox EJ, Melzack R (1976) Transcutaneous electrical stimulation and acupuncture: Comparison of treatment for low-back pain. Pain 2: 141–148PubMedGoogle Scholar
  547. 79.
    Friedberg KD, Rüfer R (1987) Opiate und opiatähnliche Verbindungen. Fischer, StuttgartGoogle Scholar
  548. 80.
    Frölich JC (1985) Wirkung von Metamizol auf die Prostaglandinsynthese des Menschen. In: Brune K, Lanz R (Hrsg) 100 Jahre Pyrazolone. Urban & Schwarzenberg, München, S 127–143Google Scholar
  549. 81.
    Gabka J (1978) Die analgetische Potenz von Valoron N. Bestimmungen der Dosisrelationen durch Reizschwellenmessungen. Krankenhausarzt 51: 431–439Google Scholar
  550. 82.
    Gerbershagen HU (1981) Neurolysis. Subarachnoid neurolytic blockade. Acta Anaesthesiol Belg 32: 45–57PubMedGoogle Scholar
  551. 83.
    Getto CJ, Sorkness CA, Howell T (1987) Antidepressants in chronic pain. J Pain Sympt Manag 2: 9–18Google Scholar
  552. 84.
    Glynn C, Dawson D, Sanders R (1988) A double-blind comparison between epidural morphine and epidural c10nidine in patients with chronic non-cancer pain. Pain 34: 123–128PubMedGoogle Scholar
  553. 85.
    Gourlay GK, Cherry DA, Cousins MJ (1986) A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25: 297–312PubMedGoogle Scholar
  554. 86.
    Greenberg HS, Kim J, Posner JB (1980) Epidural spinal cord compression from metastatic tumor: Results with a new treatment protocol. Ann Neurol 8: 361–366PubMedGoogle Scholar
  555. 87.
    Greenwald HP, Bonica JJ, Bergner M (1987) The prevalence of pain in four cancers. Cancer 60: 2563–2569PubMedGoogle Scholar
  556. 88.
    Greiner L (1985) Punktionssonographische Alkoholneurolyse der Coeliakalganglien. Dtsch Med Wochenschr 110: 833–836PubMedGoogle Scholar
  557. 89.
    Groh R, Schindera A, Werringloer M (1971) Klinische Erfahrungen mit dem neuen Analgetikum Tilidin-HCL. Med Klin 66: 1241–1245PubMedGoogle Scholar
  558. 90.
    Grond S, Zech D, Horrichs-Haermeyer G, Lehmann KA (1989) Schmerztherapie bei sterbenden Tumorpatienten. Anaesthesist [Suppl 1] 38: 107Google Scholar
  559. 91.
    Grond S, Zech D, Schug SA, Meuser T, Stobbe B, Lehmann KA (1989) Schmerzdiagnose und Schmerztherapie bei malignen urologischen Erkrankungen. Akt Uro1 20: 300–306Google Scholar
  560. 92.
    Gundert-Remy U (1987) Unerwünschte Wirkungen von Schmerz- und Rheumamitteln. In: Friedberg KD, Rüfer R (Hrsg) Antiphlogistisch und antipyretisch wirkende Analgetika - 2. Mannheimer Therapiegespräch. Fischer, Stuttgart, S 17–26Google Scholar
  561. 93.
    Haglund U (1987) Role of histamine H2 receptor antagonists in non-operative management of gastroduodenal ulcer haemorrhage. Scand J Gastroenterology [Suppl] 22/134: 39–42Google Scholar
  562. 94.
    Hankemeier U (1989) Chemische Neurolysen. In: Hankemeier U, Bowdler I, Zech D (Hrsg) Tumorschmerztherapie. Springer, Berlin Heidelberg New York Tokyo, S 62–75Google Scholar
  563. 95.
    Hankemeier U, Bowdler I, Zech D et al. (1989) Kasuistik. In: Hankemeier U, Bowdler I, Zech D (Hrsg) Tumorschmerztherapie. Springer, Berlin Heidelberg New York Tokyo S.150–156Google Scholar
  564. 96.
    Hanks GW (1984) Psychotropic drugs. Postgrad Med J 60: 881–885PubMedGoogle Scholar
  565. 97.
    Hanks GW, Trueman T, Twycross RG (1983) Corticosteroids in terminal cancer. A prospective analysis of current practice. Postgrad Med J 59: 702–706PubMedGoogle Scholar
  566. 98.
    Hanning CD, Smith G (1988) The morphine hydrogel suppository: a new sustained release rectal preparation. J Pain Sympt Manag 3/3: S19Google Scholar
  567. 99.
    Hays H (1988) The use of hyaluronidase to promote absorption of fluid and pharmacological agents from the subcutaneous space. J Pain Sympt Manag [Suppl] 3/3: 15Google Scholar
  568. 100.
    Heel RC, Brodgen TM, Speight TM, Avery GS (1979) Buprenorphine: a review of its pharmacological properties and therapeutic efficiency. Drugs 17: 81–110PubMedGoogle Scholar
  569. 101.
    Hennies HH, Friderichs E, Schneider J (1988) Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 38: 877- 880PubMedGoogle Scholar
  570. 102.
    Hilgard ER (1975) The alleviation of pain by hypnosis. Pain 1: 213–231PubMedGoogle Scholar
  571. 103.
    Houde RW (1966) On assaying analgesics in man. In: Knighton RS, Dumke PR (eds) Pain. Little, Brown, BostonGoogle Scholar
  572. 104.
    Hougs W, Skouby AP (1957) The analgesic actions of analgesics, antihistamines and chlorpromazine in volunteers. Acta Pharmacol Toxicol 13: 405–409Google Scholar
  573. 105.
    Huber HP (1978) Psychologische Wirkungspriifung eines neuen Analgetikums aus der Cyclohexanol-Reihe. Ein Beitrag zur Klärung des psychischen Abhangigkeitspotentials von Tramadol. Arzneimittelforschung 28: 189–191PubMedGoogle Scholar
  574. 106.
    Huskisson EC (1974) Measurement of pain. Lancet 9: 1127–1131Google Scholar
  575. 107.
    Ischia S, Luzzani A, Ischia A, Maffezzoli GF (1984) Bilateral percutaneous cervical cordotomy: immediate and long-term results in 36 patients with neoplastic disease. J Neurol Neurosurg Psychiatry 47: 141–147PubMedGoogle Scholar
  576. 108.
    Jay SM, Elliott C, Varni JW (1986) Acute and chronic pain in adults and children with cancer. J Consult Clin Psychol 54/5: 601–607PubMedGoogle Scholar
  577. 109.
    Jenkner FL (1988) Basic considerations I: Stimulation versus blocking. Schmerz Pain Douleur 9/3a: 140–164Google Scholar
  578. 110.
    Jensen MP, Karoly P, Braver S (1986) The measurement of clinical pain intensity. Pain 27: 117–126PubMedGoogle Scholar
  579. 111.
    Jurna I (1984) Pharmakologische Grundlagen der Schmerztherapie. Dtsch Ärztebl 18: 1441Google Scholar
  580. 112.
    Kaiko RF, Kanner R, Foley KM et al. (1987) Cocaine and morphine interaction in acute and chronic pain. Pain 31: 35–45PubMedGoogle Scholar
  581. 113.
    Kiss I (1987) Karzinomschmerzen. Springer. Berlin Heidelberg New York Tokyo (Anaesthesiologie und Intensivmedizin, Bd 196)Google Scholar
  582. 114.
    Klapetek J (1972) Das Depot-Analgetikum Develin retard bei chronischen Schmerzzuständen. Therapiewoche 22: 1402–1404Google Scholar
  583. 115.
    Kleeberg UR, Schreml W, Schönhöfer PS (1986) Schmerzbehandlung. In: Kompendium internistischer Onkologie, Teil 1. Springer, Berlin Heidelberg New York Tokyo, S 345–376Google Scholar
  584. 116.
    Klotz U (1987) Pharmakokinetik und Arzneimittelinteraktionen von antiphlogistisch and antipyretisch wirkenden Analgetika. In: Friedberg KD, Rüfer R (Hrsg) Antiphlogistisch und antipyretisch wirkende Analgetika. 2. Mannheimer Therapiegespräch. Fischer, Stuttgart S 11–16Google Scholar
  585. 117.
    Kocher R (1983) Psychopharmaka bei der Krebsschmerztherapie. Neurol Psychiatr 6 [Suppl l]: 29–35Google Scholar
  586. 118.
    Konturek SJ, Kwiecien N, Obtulowicz W et al. (1987) Double-blind placebo-controlled study on the effect of sucralfate on gastric biosynthesis of prostaglandin in normal and aspirintreated humans. In: Samuelsson B, Paoletti R, Ramwell PW (eds) Advances in prostaglandin, thromboxane and leukotriene research. Raven, New York, pp 311–314Google Scholar
  587. 119.
    Kossmann B, Ahnefeld FW, Bowdler I, Zimmermann M (1986) Schmerztherapie. Kohlhammer, StuttgartGoogle Scholar
  588. 120.
    Krell R, Hanke M (1979) Klinische Prüfung der analgetischen Wirksamkeit von Valoron N im Vergleich zu Valoron bei Tumorschmerzen. Krankenhausarzt 52: 760–764Google Scholar
  589. 121.
    Krimmer H, Pfeiffer H, Arbogast R, Sprotte G (1986) Die kombinierte Infusionsanalgesie – Ein alternatives Konzept zur postoperativen Schmerztherapie. Chirurg 57: 327–329PubMedGoogle Scholar
  590. 122.
    Kugler J, Spatz R (1984) Spektrum Antiepileptika. Aesopus, ZugGoogle Scholar
  591. 123.
    Kuttig H (1984) Radiotherapy of cancer pain. Recent Results Cancer Res 89: 191–194Google Scholar
  592. 124.
    Laitinen J (1976) Acupuncture and transcutaneous electric stimulation in the treatment of chronic sacrolumbalgia and ischialgia. Am J Chin Med 4: 169–175PubMedGoogle Scholar
  593. 125.
    Lal A, Pandy K, Chandra P, Pandi SB (1973) Dipyrone for treatment of postoperative pain. Anaesthesia 28: 43PubMedGoogle Scholar
  594. 126.
    Latasch L, Christ R (1986) Opiatrezeptoren. Anaesthesist 35: 55–65PubMedGoogle Scholar
  595. 127.
    Lay A (1987) Nebenwirkungsprofile nicht-steroidaler Antiphlogistika nach den Berichten an die Arzneimittelkommission der Deutschen Ärzteschaft in den Jahrern 1961–1983. Inauguraldissertation, Universität KölnGoogle Scholar
  596. 128.
    Lehmann TR, Russell DW, Spratt KF et al. (1986) Efficacy of electroacupuncture and TENS in the rehabilitation of chronic low back pain patients. Pain 26: 277–290PubMedGoogle Scholar
  597. 129.
    Levick S, Jacobs C, Loukas DF et al. (1988) Naproxen sodium in treatment of bone pain due to metastatic cancer. Pain 35: 253–258PubMedGoogle Scholar
  598. 130.
    Levy MH (1982) Symptom control manual. In: Cassileth BR, Cassileth PA (eds) Clinical care of the terminal cancer patient. Lea & Febiger, Philadelphia, pp 214–262Google Scholar
  599. 131.
    Lintz W, Barth H, Osterloh G, Schmidt -Böthelt E (1986) Bioavilability of enteral tramadol formulations. Arzneimittelforschung 36: 1278–1283PubMedGoogle Scholar
  600. 132.
    Lobato RD (1985) Intraventricular morphine for intractable pain associated with cancer. In: Pharmacia NU Tech (ed) Recent advances in intraspinal pain therapy. Upplands Grafiska, Uppsala, p 12Google Scholar
  601. 133.
    Lobato RD, Madrid JL, Fatela LV et al. (1984) Analgesic elicited by low-dose intraventricular morphine in terminal cancer patients. Pain [Suppl] 2: S342Google Scholar
  602. 134.
    Lobato RD, Madrid JL, Fatela LV et al. (1987) Intraventricular morphine for intractable cancer pain: rationale, methods, clinical results. Acta Anaesthesiol Scand 31 [Suppl 85]: 68–74Google Scholar
  603. 135.
    Loeser JD (1979) Dorsal column and peripheral stimulation forrelief of cancer pain. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy, vol 2. Raven, New York, pp 499–507Google Scholar
  604. 136.
    Lombardino JG (1985) Medicinical chemistry of acidid nonsteroidal antiinflammatory drugs. In: Lombardino JG (ed) Nonsteroidal antiinflammatory drugs. Wiley & Sons, New York, pp251–431Google Scholar
  605. 137.
    Londong W (1986) Anti-ulcer drugs in anti secretory doses for „cytoprotection‟ in arthritic patients? Klin Wochenschr 64 [Suppl VII]: 32–34PubMedGoogle Scholar
  606. 138.
    Long DM (1982) Pain of visceral origin. In: Youmans JR (ed) Neurological surgery, vol 6. Saunders, Philadelphia, p 3627Google Scholar
  607. 139.
    Lorenz R, Grumme T, Herrmann HD et al. (1975) Percutaneous cordotomy. In: Penholz H (ed) Advances in neurosurgery, vol 3. Springer, Berlin Heidelberg New YorkGoogle Scholar
  608. 140.
    Lundstam SOA, Leissner KH, Wahllander LA, Kral JG (1982) Prostaglandin-synthetase inhibition with diclofenac sodium in treatment of renal colic: Comparison with use of a narcotic analgesic. Lancet I: 1096–1097Google Scholar
  609. 141.
    Lynn MD, Braunstein EM, Shapiro B (1987) Pheochromocytoma presenting as musculoskeletal pain from bone metastases. Skeletal Radiol 16: 552–555PubMedGoogle Scholar
  610. 142.
    Madrid JL, Gozalo A, Fatela LV, Lobato RD (1984) Low dose cisternal morphine as a test for chronic intraventricular or intrathecal opiate therapy. Pain [Suppl] 2: S342Google Scholar
  611. 143.
    Magni G, Arsie D, De Leo D (1987) Antidepressants in the treatment of cancer pain. Pain 29: 347–353PubMedGoogle Scholar
  612. 144.
    Maltebie AA, Cavenar JO (1977) Haloperidol and analgesia: case reports. Milit Med 142: 946–948Google Scholar
  613. 145.
    Martin WR (1979) History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol 7: 273 S-279SGoogle Scholar
  614. 146.
    Martin WR (1983) Pharmacology of opioids. Pharmacol Rev 35: 283–323PubMedGoogle Scholar
  615. 147.
    McGivney WT, Grooks GM (1984) The care of patients with severe chronic pain in terminal illness. JAMA 251: 1182–1188PubMedGoogle Scholar
  616. 148.
    McQuay HJ, Carroll D, Watts PG, Juniper RP, Moore RA (1989) Codeine 20 mg increases pain relief from ibuprofen 400 mg after third molar surgery. A repeat-dosing comparison of ibuprofen and an ibuprofen-codeine combination. Pain 37: 7–13PubMedGoogle Scholar
  617. 149.
    Mertz DP (1986) Calcitonin bei Phantomschmerz. Dtsch Med Wochenschr 111: 1000PubMedGoogle Scholar
  618. 150.
    Messer J, Reitman D, Sacks HS et al. (1983) Association of adrenocorticosteröid therapy and peptic ulcer disease. N Engl J Med 309: 21–24PubMedGoogle Scholar
  619. 151.
    Meyer C, Kocher R, Felder M, Rosatti P (1985) Medikamentiise Schmerztherapie. Frage Antwort J 4: 3–17Google Scholar
  620. 152.
    Meynadier J, Chrubasik J, Dubar M, Wünsch E (1985) Intrathecal Somatostatin in terminally ill patients. A report of two cases. Pain 23: 9–12PubMedGoogle Scholar
  621. 153.
    Miser AW, Dothage JA, Miser JS (1987) Continuous intravenous fentanyl for pain control in children and young adults with cancer. Clin J Pain 3: 152–157Google Scholar
  622. 154.
    Miser AW, Narang PK, Dothage JA et al. (1989) Transdermal fentanyl for pain control in patients with cancer. Pain 37/1: 15–21PubMedGoogle Scholar
  623. 155.
    Moertel CG, Ahmann DL, Taylor WF, Schwartau N (1974) Relief of pain by oral medications. JAM A 229: 55–59Google Scholar
  624. 156.
    Moore DC (1979) Celiac (splanchnic) plexus block with alcohol for cancer pain of the upper intra-abdominal viscera. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy, vol 2. Raven, New York, pp 357–371Google Scholar
  625. 157.
    Moore DC (1979) Role of nerve block with neurolytic solutions for pelvic visceral cancer pain. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy, vol 2. Raven, New York, pp 593–596Google Scholar
  626. 158.
    Moore DK (1986) Continuous subcutaneous morphine for the control of severe chronic pain. Oncol Nurs Forum 13/4 [Suppl]: 52Google Scholar
  627. 159.
    Moore J, Dundee JW (1961) Alterations in response to somatic pain associated with anaesthesia. VII: The effects of nine phenothiazine derivates. Br J Anaesth 33: 422–431PubMedGoogle Scholar
  628. 160.
    Motsch J (1986) Therapie des Schmerzes durch Nervenblockaden. Saari Ärztebl 6: 399–403Google Scholar
  629. 161.
    Motsch J, Schüder G, Bier B (1987) Use of portable pumps for continuous intrathecal narcotics infusion. Anaesthesist 36: 391Google Scholar
  630. 162.
    Müller H, Aigner K, Worm I, Lobisch M et al. (1984) Langzeit-Erfahrungen mit derkontinuierlichen periduralen Opiatanalgesie mittels implantierter Pumpen. Anaesthesist 33: 433–439PubMedGoogle Scholar
  631. 163.
    Müller H, Aigner K, Zierski J (1985) Behandlung von Tumorschmerz mit Pumpsystemen zur rückenmarknahen Opiatapplikation. Dtsch Ärzteb 182/35: 2475–2484Google Scholar
  632. 164.
    Müller H, Börner U, Zierski J, Hempelmann G (1987) Intrathecal baclofen for treatment of tetanus-induced spasticity. Anaesthesiology 66/1: 76–79Google Scholar
  633. 165.
    Müller H, Lüben V, Zierski J, Hempelmann G (1988) Long term spinal opiate treatment. Acta Anaesthesiol Belg [Suppl 2] 39/2: 83–86PubMedGoogle Scholar
  634. 166.
    Müller P, Dammann HG, Simon B (1986) Akute Schädigung der Magenschleimhaut durch Acetylsalicylsäure. Arzneimittelforschung 36 (I)/2: 265–268Google Scholar
  635. 167.
    Mullan S, Hosobuchi Y (1968) Respiratory hazards of high cervical percutaneous cordotomy. J Neurosurg 22: 291–297Google Scholar
  636. 168.
    Nehme AE, Warfield CA (1987) Cryoanalgesia: Freezing of peripheral nerves. Hosp Pract [Off] 22(1A): 71–72, 77Google Scholar
  637. 169.
    NN (1988) Gastrointestinale Effekte nichtsteroidaler Antirheumatika. Berichtzum Symposium „Arzneimittel-induzierte dyspeptische Beschwerden und peptische Läsionen im oberen Gastrointestinaltrakt, Aachen. Rheuma + Schmerz Entzündung 8/8: 46–47Google Scholar
  638. 170.
    Nyberg F, Almay BGL, Johansson F et al. (1988) Opioid peptides and substance p in cerebrospinal fluid - increased concentration after high frequency transcutaneous electrical nerve stimulation. Schmerz Pain Douleur 9/3a: 165–174Google Scholar
  639. 171.
    Obbens EAMT, Hill CS, Leavans ME et al. (1987) Intraventricular morphine administration for control of chronic cancer pain. Pain 28: 61–68PubMedGoogle Scholar
  640. 172.
    Owitz S, Koppolu S (1983) Celiac plexus block: An overview. Mt Sinai J Med (NY) 50/6: 486–490Google Scholar
  641. 173.
    Pannuti F, Rossi AP, Jafelice G et al. (1982) Control of chronic pain in very advanced cancer patients with morphine hydrochloride administered by oral, rectal and sublingual route. Clinical report and preliminary results on morphine pharmacokinetics. Pharmacol Res Commun 14/4: 369–380PubMedGoogle Scholar
  642. 174.
    Patel CV, Koppikar MG, Patel MS (1980) A double-blind comparison of dipyrone in the treatment of postoperative pain. CUff Med Res Opin 6: 624Google Scholar
  643. 175.
    Payne R (1987) Anatomy, physiology and neuropharmacology of cancer pain. Med Clin North Am 71: 153–167PubMedGoogle Scholar
  644. 176.
    Penn RD, Kroin JS (1984) Intrathecal baclofen alleviates spinal cord spasticity. Lancet I: 1078Google Scholar
  645. 177.
    Pichlmaier H, Thielemann-Jonen I, Zech D (1988) Die palliative Behandlung von terminal Tumorkranken. Internist 29: 26–33PubMedGoogle Scholar
  646. 178.
    Pohl S (1984) Hormonelle Analgesie mit Calcitonin. Schmerz 3: 93Google Scholar
  647. 179.
    Pollard M, Phyllis HL (1986) The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells. Prostate 8: 81–86PubMedGoogle Scholar
  648. 180.
    Porges P, Zdrahal F (1985) Die intrathekale Alkoholneurolyse der unteren sakralen Wurzeln beim inoperablen Rektumkarzinom. Anaesthesist 34/11: 627–629PubMedGoogle Scholar
  649. 181.
    Portenoy RK, Fole KM (1986) Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain 25: 171–186PubMedGoogle Scholar
  650. 182.
    Probst C (1983) Neurochirurgische Möglichkeiten beim Karzinomschmerz. Schweiz Rundsch Med Prax 72/6: 171–176PubMedGoogle Scholar
  651. 183.
    Ralston SH, Alzaid AA, Gardner MD, Boyle IT (1986) Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Br Med J 292: 1549–1550Google Scholar
  652. 184.
    Rawal N, Arnér S, Gustafsson LL, Allvin R (1987) Present state of extradural and intrathecal opioid analgesia in Sweden. Br J Anaesth 59: 791–799PubMedGoogle Scholar
  653. 185.
    Regnard CFB, Davies A (1986) A guide to symptom relief in advanced cancer. Haigh & Hochland, ManchesterGoogle Scholar
  654. 186.
    Reid W, Watt JK, Gray TG (1970) Phenol injection of the sympathetic chain. Br J Surg 57: 45–50PubMedGoogle Scholar
  655. 187.
    Richardson PH, Vincent CA (1986) Acupuncture for the treatment of pain: a review of evaluative research. Pain 24: 15–40PubMedGoogle Scholar
  656. 188.
    Richter HP, Schmidt K (1983) Neurochirurgische Behandlungsmöglichkeiten maligner Schmerzen. Chirurg 54: 789–794PubMedGoogle Scholar
  657. 189.
    Robinson RG, Spicer JA, Preston DF et al. (1987) Treatment of metastatic bone pain with 89Strontium. Int J Rad Appllnstrum [B] 14/3: 219–22Google Scholar
  658. 190.
    Rogers AG (1987) The use of continuous subcutaneous infusion of narcotics in chronic cancer pain. J Pain Sympt Manag 2/3: 167–168Google Scholar
  659. 191.
    Rohdewald P, Neddermann E (1988) Dosisabhangigkeit der analgetischen Wirkung von Metamizol. Anaesthesist 37: 150–155PubMedGoogle Scholar
  660. 192.
    Rosomoff HL (1969) Bilateral percutaneous cervical radiofrequency cordotomy. J Neurosurg 31: 41–46PubMedGoogle Scholar
  661. 193.
    Rosomoff HL, Caroll F, Brown J, Sheptak P (1965) Percutaneous radiofrequency cervical cordotomy; Technique. J Neurosurg 23: 639–644PubMedGoogle Scholar
  662. 194.
    Rumore NM, Schlichting DA (1986) Clinical efficacy of antihistaminics as analgesics. Pain 25: 7–22PubMedGoogle Scholar
  663. 195.
    Ryan JR, Vargas R, Clay GA, McMahon FG (1987) Role of Misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med 83 [Suppl 1A]: 41–44PubMedGoogle Scholar
  664. 196.
    Sadove MS, Levin MJ, Rose RF, Schwartz L, Witt FW (1954) Chlorpromazine and narcotics in the management of pain of malignant lesions. AMA 155: 626–628Google Scholar
  665. 197.
    Säwe J (1986) High dose morphine and methadone in cancer patients. Clin Pharmacokin et 11: 87–106Google Scholar
  666. 198.
    Saris SC, Silver JM, Vieira JFS et al. (1986) Sacrococcygeal rhizotomy for perineal pain. Neurosurgery 18/5: 789–793Google Scholar
  667. 199.
    Schell HW (1972) Adrenal corticosteroid therapy in far-advanced cancer. Geriatrics 27: 131–141PubMedGoogle Scholar
  668. 200.
    Schild H, Günther R, Hoffmann J, Goedecke R (1983) CT-gesteuerte Blockade des Plexus Coeliacus mit ventral em Zugang. Fortschr Röntgenstr 139/2: 202–205Google Scholar
  669. 201.
    Schroth HJ, Steinsträßer A, Berberich R, Kloss G (1985) Untersuchungen zur Wirksamkeit von Metamizol auf die Motilität der ableitenden Harnwege. In: Brune K, Lanz R (Hrsg) 100 Jahre Pyrazolone - Eine Bestandsaufnahme. Urban & Schwarzenberg, München, S 145–154Google Scholar
  670. 202.
    Schroth HJ, Garth H, Rupp St, Steinsträßer A (1986) Wirkung von Metamizol auf die Harnwegs-Motilität. Fortschr Med 104/18: 378–382Google Scholar
  671. 203.
    Schroth HJ, Garth H, Rupp S, Oberhausen E (1987) Wirkung von Metamizol auf die Kontraktilität der Gallenblase. Fortschr Med 105/7: 136–138PubMedGoogle Scholar
  672. 204.
    Schüle-Hein K (1989) Palliative Strahlenbehandlung. In: Hankemeier U, Bowdler I, Zech D (Hrsg) Tumorschmerztherapie. Springer, Berlin Heidelberg New York Tokyo S. 102–123Google Scholar
  673. 205.
    Schug SA, Zech D, Dörr U (1988) The use of morphine in cancer pain - a german problem? J Pain Sympt Manag 3/3: 26Google Scholar
  674. 206.
    Schug SA, Zech D, Dörr U (1990) Cancer pain management according to WHO analgesic guidelines. J Pain Sympt Manag 5, 1: 27–32Google Scholar
  675. 207.
    Seemann H, Schug S, Zech D, Zimmermann M (1988) Kongreßbericht „Second International Congress on Cancer Pain‟ New York: Bewertung und Behandlung von Schmerzen bei Tumorpatienten. Med Klin 83/24: 846–853Google Scholar
  676. 208.
    Siegfried J (1988) Electrostimulation and neurosurgical measures in cancer pain. Recent Results Cancer Res 108: 28–32PubMedGoogle Scholar
  677. 209.
    Siegfried J, Kühner A, Sturm V (1984) Neurosurgical treatment of cancer pain. In: Zimmermann M, Drings P, Wagner G (eds) Pain in the cancer patient. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  678. 210.
    Siegmeth W (1986) Medikamentöse Rheumatherapie. In: Wörz R (Hrsg) Pharmakotherapie bei Schmerz. VHC, Weinheim, S 191–237Google Scholar
  679. 211.
    Silberstein EB, Williams C (1985) 89Strontium for the pain of osseous metastases. J Nuc1 Med 26/4: 345–348Google Scholar
  680. 212.
    Sjölund B, Terenius L, Eriksson M (1977) Increased CSF-Ievels of endorphins after electroacupuncture. Acta Physiol Scand 100: 382–384PubMedGoogle Scholar
  681. 213.
    Sloan PA, Thirlwell M, Maroun J, Besner JG (1987) The pharmacokinetics of sustained-release morphine tablets. Anesth Analg 66: S 160Google Scholar
  682. 214.
    Spiegel D (1985) The use of hypnosis in controlling cancer pain. CA 35/4: 221–231PubMedGoogle Scholar
  683. 215.
    Spiegel D, Bloom JR (1983) Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 45: 333–339PubMedGoogle Scholar
  684. 216.
    Spiegel D, Bloom JR, Yalom ID (1981) Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry 38: 527–533PubMedGoogle Scholar
  685. 217.
    Stammbaugh JE, Lane C (1983) Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination. Cancer Invest 1: 111–117Google Scholar
  686. 218.
    Steude U (1983) Neurochirurgische Verfahren zur Behandlung von Krebsschmerzen. Arch Gynecol 235(1–4): 298–306PubMedGoogle Scholar
  687. 219.
    Stillman MJ, Payne R, Foley KM (1988) Perineal pain in cancer patients. J Pain Sympt Manag 3: 21Google Scholar
  688. 220.
    Stoelting RK (1987) Pharmacology and physiology in anesthetic practice. Lippincott, PhiladelphiaGoogle Scholar
  689. 221.
    Su CF, Liu MY, Lin MT (1987) Intraventricular morphine produces pain relief, hypothermia, hyperglycaemia and increased prolactin and growth hormone in patients with cancer pain. J Neurol 235: 105–108PubMedGoogle Scholar
  690. 222.
    Sunshine A, Laska E (1975) Nefopam and morphine in man. Clin Pharmacol Ther 18: 530–534PubMedGoogle Scholar
  691. 223.
    Swerdlow M (1979) Subarachnoid and extradural neurolytic blocks. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy, vol 2. Raven, New York, pp 325–337Google Scholar
  692. 224.
    Swerdlow M (1987) Role of chemical neurolysis and local anaesthetic infiltration. In: Swerdlow M, Ventafridda V (eds) Cancer pain. MTP, Lancaster, pp 105–128Google Scholar
  693. 225.
    Swerdlow M, Cundill JG (1981) Anticonvulsant drugs used in the treatment ofiancinating pain. Anaesthesia 36: 1129–1132PubMedGoogle Scholar
  694. 226.
    Sykes NP (1987) Pain control in terminal cancer. Int Disabil Stud 9: 33–37PubMedGoogle Scholar
  695. 227.
    Szczeklik A, Czerniawska G, Nizankowska E (1985) Allergische und pseudoallergische Reaktionen auf Pyrazolonpräparate. In: Brune K, Lanz R (Hrsg) 100 Jahre Pyrazolone. Urban & Schwarzenberg, Miinchen, S 247–252Google Scholar
  696. 228.
    Takeda F (1988) Japan’s WHO cancer pain relief program. J Pain Sympt Manag 3/3: S27Google Scholar
  697. 229.
    Tempest SM (1982) Pain control in terminal illness. Pharmaceut J 229: 555–560Google Scholar
  698. 230.
    The International Agranulcytosis and Aplastic Anemia Study (1986) Risks of agranulocytosis and aplastic anemia, a first report of their relation to drug use with special reference to analgesics. JAMA 256: 1749–1757Google Scholar
  699. 231.
    Tigerstedt I, Sepponen J, Tammisto T, Turunen M (1977) Comparison of nefopam and pethidin in postoperative pain. Br J Anaesth 49: 1133–1138PubMedGoogle Scholar
  700. 232.
    Tsai SK, Mok MS, Hung HL, Lippmann M (1988) Analgesic effect of intrathecal ketamine in primates. Anesth Analg 67: S234Google Scholar
  701. 233.
    Turnbull F (1979) The nature of pain that may accompany cancer of the lung. Pain 7: 371–375PubMedGoogle Scholar
  702. 234.
    Turner JA, Chapman CR (1982) Psychological interventions for chronic pain: a critical review. I. Relaxation training and biofeedback. Pain 12: 1–21PubMedGoogle Scholar
  703. 235.
    Turner JA, Chapman CR (1982) Psychological interventions for chronic pain: a critical review. II. Operant conditioning, hypnosis, and cognitive-behavioral therapy. Pain 12: 23–46PubMedGoogle Scholar
  704. 236.
    Twycross RG (1978) The assessment of pain in advanced cancer. J Med Ethics 4: 112–116PubMedGoogle Scholar
  705. 237.
    Twycross RG (1979) Non-narcotic, corticosteroids and psychotropic drugs. In: Twycross RG, Ventafridda V (eds) The continuing care of terminal cancer patients. Pergamon, New York pp 117–1134Google Scholar
  706. 238.
    Twycross RG (1980) Medical treatment of cancer pain. Bull Cancer 67: 209–216PubMedGoogle Scholar
  707. 239.
    Twycross RG, Fairfield S (1982) Pain in far advanced cancer. Pain 14: 303–310PubMedGoogle Scholar
  708. 240.
    Twycross RG, Lack SA (eds) (1983) Non-narcotic analgesics. In: Symptom control in far advanced cancer: Pain relief, Pitman, London, pp 117–148Google Scholar
  709. 241.
    Twycross RG, Lack SA (1983) Symptom control in far advanced cancer: Pain relief. Pitman, LondonGoogle Scholar
  710. 242.
    Twycross RG, Lack SA (1984) Therapeutics in terminal cancer. Pitman, LondonGoogle Scholar
  711. 243.
    Ventafridda V (1984) Use of analgesic drugs in cancer pain. In: Benedetti D (ed) Advances in pain research and therapy, vol 7. Raven, New YorkGoogle Scholar
  712. 244.
    Ventafridda V, Martino G (1976) Clinical evaluation of subarachnoid neurolytic blocks in intractable cancer pain. In: Bonica JJ, Albe-Fessard D (eds) Advances in pain research and therapy, vol 1. Raven, New York, pp 699–703Google Scholar
  713. 245.
    Ventafridda V, Olivieri E, Caraceni A et al. (1987) A retrospective study on the use of oral morphine in cancer pain. J Pain Sympt Manag 2: 77–81Google Scholar
  714. 246.
    Ventafridda V, Sganzerla EP, Fochi G, Pozzi G, Gordini G (1979) Transcutaneous nerve stimulation in cancer patients. In: Bonica JJ, Ventafridda V (eds) Advances in pain, research and therapy, vol 2. Raven, New York, pp 509–515Google Scholar
  715. 247.
    Ventafridda V, Tamburini M, Caraceni A et al. (1986) A validation study of the WHO method for cancer pain relief. Cancer 59: 850–856Google Scholar
  716. 248.
    Waldman SD, Coombs DW (1989) Selection of implantable narcotic delivery systems. Anesth Analg 68: 377–384PubMedGoogle Scholar
  717. 249.
    Waldmeier PC (1987) Zur Pharmakologie der Antidepressiva beim chronischen Schmerz. In: Kocher R (Hrsg) Psychopharmaka bei chronischem Schmerz. Ciba-Geigy, Basel, S 56Google Scholar
  718. 250.
    Walker VA, Hoskin PJ, Hanks GW, White ID (1988) Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Sympt Manag 3/3: 145–149Google Scholar
  719. 251.
    Walsh TD (1984) Oral morphine in chronic cancer pain. Pain 18: 1–11PubMedGoogle Scholar
  720. 252.
    Watson PN, Evans RJ (1987) Intractable pain with lung cancer. Pain 29: 163–173PubMedGoogle Scholar
  721. 253.
    Way EL, Young JM, Kemp JW (1965) Metabolism of heroin and its pharmacological implications. Bull Narc 17/1: 25–33Google Scholar
  722. 254.
    Westerling D, Andersson KE (1984) Rectal administration of morphine hydrogel: absorption and bioavailability in women. ActaAnaesthesiol Scand 28: 540–543Google Scholar
  723. 255.
    White JC, Sweet WH (1979) Anterolateral cordotomy: open versus closed, comparison of end results. Adv Pain Res Ther 3: 911–919Google Scholar
  724. 256.
    WHO (1986) Cancer pain relief. GenfGoogle Scholar
  725. 257.
    Wilder-Smith CH, Senn HJ (1987) Schmerzen bei Tumorpatienten. Arzneimitteltherapie 5: 139–151Google Scholar
  726. 258.
    Wörz R (1986) Karzinomschmerztherapie mit Arzneimitteln. In: Worz R (Hrsg) Pharmakotherapie bei Schmerz. VHC, Weinheim, S 273–290Google Scholar
  727. 259.
    Wörz R, Berlin J (1989) Behandlung chronischer Schmerzsyndrome mit Antidepressiva. Schmerz 3/1 : 1–7PubMedGoogle Scholar
  728. 260.
    Xiang L, Bing Z, Shou-xin Z (1986) Relationship between electroacupuncture analgesia and descending pain inhibitory mechanism of nucleus raphe magnus. Pain 24: 383–396Google Scholar
  729. 261.
    Yaksh TL, Müller H (1982) Spinal opiate analgesia. Experimental and clinical studies. Springer, Berlin Heidelberg New York Tokyo (Anaesthesiologie und Intensivmedizin 144)Google Scholar
  730. 262.
    Yaksh TL, Rudy TA (1978) Narcotic analgetics: CNS-sites and mechanism of action. Pain 4: 299–359PubMedGoogle Scholar
  731. 263.
    Zech D (1988) Ursache, Lokalisation und Behandlung der Schmerzen bei Patienten mit urologischen Malignomen. In: Hermann G, Heyer J, Engström P (Hrsg) Söldener Gespräche 1988, Wissenschaft und Forschung, Solingen, S 40–56Google Scholar
  732. 264.
    Zech D, Schug SA, Horsch M (1988) Therapiekompendium Tumorschmerz. Perimed, ErlangenGoogle Scholar
  733. 265.
    Zimmermann M (1984) Lokalisierte Eingriffe am Nervensystem zur Schmerzbehandlung. In: Zimmermann M, Handwerker O (Hrsg) Schmerz - Konzepte und arztliches Handeln. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  734. 266.
    Zimmermann M (1984) Physiologie von Nozizeption und Schmerz. In: Zimmermann M, Handwerker O (Hrsg) Schmerz - Konzepte und ärztliches Handeln. Springer, Berlin Heidelberg New York Tokyo, S 1–42Google Scholar
  735. 267.
    Zoppi M, Hoigne R, Keller MF, Streit F, Hess T (1983) Blutdruckabfall unter Oipyron (Novaminsulfon-Natrium). Schweiz Med Wochenschr 113: 1768–1770PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • H. Pichlmaier
  • G. Spilker
  • G. Germann
  • M. H. Hackenbroch
  • J. Rütt
  • S. Said
  • W. Kruis
  • R.-P. Müller
  • R. Zankovich
  • M. Pfreundschuh
  • V. Diehl
  • I. Krüger
  • G. Friedmann
  • W. Gross-Fengels
  • H. O. Klein
  • W. F. Jungi
  • I. Jonen-Thielemann
  • J. M. Müller
  • D. Zech
  • W. Buzello

There are no affiliations available

Personalised recommendations